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  Initiation of transcription is achieved through a series of coupled binding equilibria 
commenced by interactions between DNA-bound transcriptional activators and coactivators. 
Abnormalities in either the activator or coactivator can disrupt or enhance the activator-
coactivator interaction and result in serious diseases. Hence there is great need to understand the 
mechanism of these activator-coactivator interactions and design artificial transcriptional 
regulators as probes or potential therapeutics. However, the key mechanistic features responsible 
for the differential transcriptional output of these activators are yet to be well-defined. The focus 
of this dissertation work has been to dissect the kinetic and structural characteristics of 
transcriptional activator-coactivator interactions and examine the effects of small molecule 
modulators on these interactions. 
Utilizing fluorescence stopped-flow, we measured the transient-state kinetics of the 
transcriptional activation domains (TADs) of the activators Gal4, Gcn4 and VP16 in their DNA-
bound forms binding to the coactivator Med15. We determined that they interact through the 
xv 
 
same two-step binding mechanism: an initial rapid bimolecular association step followed by a 
slower conformational change step. Additional analysis suggests that the tendency for an 
activator to undergo conformational change correlates with both its overall affinity to the 
coactivator and its transcriptional activity in vivo.                           
This mechanistic study of activator-coactivator interactions was further applied to the more 
conformationally defined system of TADs (MLL and pKID) binding cooperatively to the 
coactivator KIX. The study showed that both TADs bind to KIX through a two-step mechanism 
similar to that of TADs binding to Med15. A small molecule fragment 1-10 from a Tethering 
screen covalently tethers to a cysteine mutant of the coactivator KIX domain of CBP at the MLL 
binding site. The additional stabilizing effect of 1-10 tethering to KIX enabled me to obtain a 
crystal structure of 1-10—KIX L664C. This is the first crystal structure of the KIX domain of 
CBP, and provides a high-resolution snapshot of this domain. Additionally, I found that 1-10 
elicits varying allosteric effects on the opposite pKID binding site of KIX, depending on the site 
at which it tethers. This reveals 1-10 as a powerful small molecule probe to dissect the allosteric 
mechanisms of the KIX-pKID interaction. I used 1-10 tethered at different cysteine mutations as 
well as the MLL peptide as probes to study the allosteric effects of KIX’s pKID binding through 
transient-state kinetics. I also observed that the dissociation rate constant koff between pKID and 
KIX correlated with their overall binding affinity KD. As koff  better reflects the slower 
conformational change step of this interaction, this again suggests that conformational change 
drives overall affinity between pKID and KIX. 
In conclusion, I have elucidated the transient-state kinetic mechanism of two activator-
coactivator interaction systems, and have shown the potential of a small molecule as a powerful 
probe for dissecting interaction mechanisms in ways unique to native peptide ligands.  
1 
 
Chapter 1 Introduction 
 
A. Introduction 
In response to certain signals, transcriptional activators bind to their specific DNA 
recognition sites and recruit proteins known as coactivators followed by components of the 
transcriptional machinery to the promoter site of the gene, thus initiating transcription (Figure 
1.1). Transcriptional activator-coactivator interactions play a key role in regulating the 
transcription of genes in the cell. Many diseases are known to be caused by abnormalities in 
transcriptional activators and/or their regulation networks, such as cancer and developmental 
disorders.
1–5
 This suggests the possibility of developing artificial transcriptional modulators for 
therapeutic applications.
6–8
 However, the mechanism of transcriptional activator-coactivator 
interactions in the transcriptional machinery remains poorly understood and has hampered the 
progress of targeted development of artificial activator replacements or inhibitors. The work 
outlined in this dissertation focuses on the elucidation of the mechanism of transcriptional 
activator-coactivator interactions through the study of their conformation and properties. In this 
chapter, I will briefly discuss the complex nature of protein-protein interactions, with an 
emphasis on transcriptional activator-coactivator interactions. In particular, the advancements 
and limitations in mechanistic studies of these interactions will be discussed, as well as their 




Figure 1.1 Cartoon representation of the transcriptional activation process. A modular 
transcriptional activator binds to DNA, and in turn recruits coactivators and chromatin remodeling 
enzymes, which also act as a scaffold to recruit the general preinitiation complex containing RNA 





B. Transcriptional regulation 
B.1. Overview of transcriptional regulation  
Transcription is a highly regulated and complicated process orchestrated by a vast protein 
network consisting of approximately 300 proteins in yeast and up to 3000 in humans. The 
ultimate output of this elaborate cascade is the localization of RNA polymerase II (RNA Pol II) 
to the promoter region of a gene and the catalysis of the template-based synthesis of mRNA. 
General transcription factors along with RNA Pol II form the preinitiaion complex. These are the 
component that are necessary for basal level transcription.
10,11
 These five general transcription 
factors, referred to as TFIIB, TFIID, TFIIE, TFIIF and TFIIH, are responsible for promoter 
recognition and unwinding the promoter DNA.
12
 Apart from these key players, the myriad 
proteins that regulate the activation and recruitment of the preinitiation complex leading to 
transcription can be separated into two types. The first type is transcriptional activators that bind 
directly to DNA. The second type are transcriptional coactivators and co-repressors, protein 
complexes that do not directly bind to DNA, but instead bind to the  transcriptional activators 





 These components along with the preinitiation complex are responsible 
for activated transcription in cells. The emphasis of this dissertation is the interaction between 
these transcriptional activators and the coactivators they interact with (Figure 1.1). 
 
B.2. Transcriptional activators 
Transcriptional activators are modular proteins with domains that are interchangeable.
15
 The 
major domains are the DNA binding domain (DBD) and the transcriptional activation domain 
(TAD).
16,17
 Various transcriptional activators also have additional domains such as a nuclear 
localization sequence (NLS) or a nuclear export sequence (NES), and for certain transcriptional 
activators such as hormone receptors there is a ligand binding domain.
18
 DNA binding domains 
usually bind to the gene response elements on DNA with high specificity and high affinity 
(nanomolar KD)
19
 via several different types of motifs. A few well studied motifs include the 
helix-turn-helix motif,
20
 the zinc finger motif
21
 and a more simple zinc cluster motif,
22
 the basic 
leucine zipper motif,
23
 and the basic helix-loop-helix motif.
24
 Unlike the well-studied DBDs, 
there is less information known about transcriptional activation domains (TADs), which are 
responsible for recruiting coactivators and the general transcriptional machinery via protein-
protein interactions. These domains tend to be less structured and are often rich in acidic amino 
acids.
25
 Many TADs are hub proteins (which will be discussed in the following section) that can 
bind to multiple binding partners at either the same or different sites with high specificity.
26–30
 
However, the mode of action of TADs, such as their specific binding partners and the 






B.3. Transcriptional coactivators 
Transcriptional coactivators are a class of proteins that modulate transcriptional activity by 
protein-protein interactions between transcriptional activators and the general transcription 
factors along with RNA Polymerase II. One important coactivator is the Mediator complex. 
Mediator is a 25-30 subunit protein complex that is unique to eukaryotes, and is conserved from 
yeast to humans.
31–33
 It acts as a molecular bridge connecting transcriptional activators with 
RNA Pol II.
34
 Although it is not required for basal level transcription in vitro, Mediator is an 
integral part of the preinitiation complex, and is sometimes considered a general transcription 
factor instead of a coactivator. The other transcriptional coactivators can be organized into two 
classes: chromatin modification complexes and chromatin remodeling complexes. Chromatin 
modification complexes such as histone acetyl transferases (HATs)
35
 act by post translationally 
modifying histones (acetylation, methylation, phosphorylation, ubiquitination, sumoylation, etc.) 
to control access of proteins to the DNA. Chromatin remodeling complexes, such as the 




The emphasis of my thesis work is on the mechanism of the protein-protein interactions 
between transcriptional activators and coactivators, which will be discussed in the following 
section. 
 
C. Protein-protein interactions (PPIs) in transcription 
C.1. Diverse functions and structural architecture of cellular protein-protein interactions 
 Protein-protein interactions (PPIs) govern most cellular processes. The protein interactome 
is an intricate and complicated network often depicted as an interwoven web of interaction nodes 
5 
 
and edges (Figure 1.2). It has been estimated that a human cell may contain approximately 
130,000 binary interactions between proteins.
37
 Even in one of the simpler eukaryotic organisms, 
Saccharomyces cerevisiae, there is estimated to be 16,000-25,000 different interaction pairs 
(excluding homotypic interactions). Enormous effort has been directed towards this field of 
study in the recent decades and, despite considerable advancements in the understanding of PPIs, 
there is still a great amount that is unknown about these interactions, such as the underlying 




There is a great range of diversity in the nature of protein-protein interactions, from strong, 




particular interest to us are transient 
protein-protein interactions, where the 
separate protein monomers can exist 
either on their own or in complex in 
vivo, and dynamically interchange 
between free and complex form.
40
 
These PPIs play an important role in 
cell signaling and homeostasis, and 
can respond to extra- and intra-
cellular changes. To this end, changes 
in the local environment can cause 
such actions as protein 
 
Figure 1.2 Network diagram showing a map of 
protein-protein interactions in a yeast 
(Saccharomyces cerevisiae) cell. This cluster includes 
78 percent of the proteins in the yeast proteome. The 
color of a node represents the phenotypic effect of 
removing the corresponding protein (red, lethal; 
green, nonlethal; orange, slow growth; yellow, 





 changes in local protein concentration (such as in the nucleosome),
42
 and 
changes in physiological conditions (such as pH, temperature or ionic strength)
43,44
 that would 
affect the binding affinities of the proteins.
45,46
 Furthermore, these changes could initiate a 
molecular signal by allosteric or cooperative ligand binding or covalent modification.
45
 Different 
transient PPIs are commonly compared by examining several properties of the protein-protein 
interaction interface, including the contact surface area (which can range from ~500 Å to ~2000 
Å), the planarity of the interface surface, the percent of polar residues at the interface, and the 
GAP index (which describes the degree of complementary of the interacting surfaces).
45
 For 
example, weaker interactions will often have a smaller and flatter interface and less 
complementary surfaces (Figure 1.3).
46
 It has also been shown that usually a cluster of a few 
amino acids at the binding interface contribute to most of the binding energy, called the “hot 
spots” or “hot spot regions”, and designing mutations or small molecules that target these hot 




Figure 1.3 Example of protein-protein interactions of high affinity and large contact surface area 
and low affinity and low contact surface area. a) Heterodimer of Ef-Ts (purple) and Ef-Tu (blue) 




 b) Homodimer 








C.2. Transcription factors as hub proteins--multispecificity and multifunctionality 
 In the PPI network, of specific interest are the proteins that are at the “nodes” of the web, 
otherwise known as hub proteins.
51,52
 Hub proteins that bind to different proteins at the same 
binding surface at different times are generally referred to as single-interface hubs, while hub 
proteins that are able to bind to multiple proteins at the same time are referred to as multi-
interface hubs (Figure 1.4).
53
 
Many transcription factors have 
been shown to be hub proteins, such as 
subunits of the Mediator complex and 
the paralogue coactivators 
CBP/p300.
51,54–56
 Much research has 
been directed towards the ability of 
these hub proteins to exhibit 
multispecificity, as well as 
multifunctionality, their ability to be 
involved in multiple non-overlapping pathways. 
A number of studies suggest that structural plasticity plays a key role in the multispecificity 
of hub proteins.
57–59
 The ability to be structurally flexible enables these proteins to undergo 
conformational change and adapt to various partner proteins as required. Studies also show that 
while the single-interface hub proteins tend to be more disordered, both single- and multi-
interface hubs have highly structured binding interfaces; however the binding partners of these 
hubs tend to be highly disordered.
59
 This is exemplified in the example of the hub protein, the 
KIX domain of CBP: KIX is a three helix bundle, however the TADs binding to KIX at two 
 
Figure 1.4 Schematic representation of protein 
interaction networks. Single-interface hubs bind to 
different partners at different times while multi-
interface hubs bind to multiple partners at the same 






different sites (MLL, pKID, c-Myb and p53) are all disordered in isolation and only assume 
structure when bound.
30,60–62
 A large-scale study on the comparison of non-hub interactions and 
hub interactions (mainly single-interface hub proteins) summarized several characteristics of 
common interface motifs of hub proteins: lower conservation of “hot spot” clusters (known as 
“hot regions”) at the interface; smaller accessible surface area at a more planar interface; a high 
prevalence of α-helices at multifunctional interfaces; and imperfect packing at the interface with 
more polar residues. These characteristics could also explain the multispecificity of hub proteins. 
How transcription factor hub proteins still retain a level of specificity and are able to function 
in multiple pathways without creating debilitating overlaps and “short circuiting” is a more 
complicated question. Several hypotheses regarding this phenomenon have been put forth, but 
researchers are far from fully understanding this mechanism. Various studies suggest hub 
proteins can specifically recognize which binding partners to bind to through mechanisms such 
as “switches” in the form of post translational modifications and interfaces being used in 
pathways in a sequential matter when a substrate-such as ubiquitin-must be passed from one 
protein to another.
63
 In a more general observation, an important factor again appears to be the 
conformational flexibility of the protein.
64
 While buried interface residues tend to be important 
for recognizing multiple partners, the exposed interface residues impart specificity for a 
particular ligand, and diverse side-chain torsion angles of hub proteins are important in 
accommodating binding to multiple targets.
65
  
Additionally, allosteric interactions play a key role in multifunctionality and regulation as 
well.
66
 This is commonly seen among transcription factor hub proteins such as the KIX domain 
of CBP/p300.
67–69




C.3. PPIs between transcriptional activators and coactivators  
 As with any complicated signaling network, protein-protein interactions is an integral 
component in the mechanism by which transcriptional activators and coactivators work together 
to regulate transcription. These PPIs can be classified into two categories: more stable 
interactions between several subunits of a complex, commonly found in coactivator complexes 
such as SWI/SNF, SAGA and Mediator (Figure 1.55a); and weaker, transient interactions 
between transcriptional activators and coactivators/suppressors (Figure 1.5b). While the stable 
complexes are relatively well defined now by techniques such as co-purification
70
 and affinity 
capture
71
 and some even directly visualized by x-ray crystallography
72
 and electron microscopy
32
, 
the transient activator-coactivator interactions are more elusive and difficult to characterize, both 
conformationally and kinetically. 
 
Figure 1.5 Cartoon depiction of a) multiple subunits stably interacting with each other, forming the 
Mediator complex. Figure modified from Malik et al, 2010.
54
 b) the same transcriptional activation 
domain (TAD) interacting with multiple partners such as histone modification coactivators (CBP), 




A closer look at the nature of activator-coactivator interactions explain to some extent why 
these are difficult to fully understand: most coactivators and activators would qualify as hub 
proteins, where one protein will have multiple binding partners involved in several different 
pathways (Figure 1.6), not surprisingly both transcriptional activators and coactivators tend to be 




Figure 1.6 Interaction networks (incomplete for clarity) of transcriptional activator Gal4 and 
coactivator CREB Binding Protein (CREBBP) show that they are hub proteins and demonstrate the 
complexity of transcriptional activator-coactivator interactions. Networks generated by STRING, a 
database of PPIs based on experimental data and computational predictions.
74
 Associations with 
higher confidence are represented by thicker lines. 
 
  Extensive effort has been made to reveal this network of interactions. Indeed, over the past 
few decades, enormous progress has been made in identifying the coactivator binding partners of 
various transcriptional activators (Figure 1.7) through a variety of in vivo techniques such as 
affinity capture,
75
 phenotypic suppression or enhancement, protein-fragment complementation 






Figure 1.7 Timeline of the identification of transcriptional activator targets since the 1980s. The 




While these studies seek to answer the question of “who” the proteins interact with, another 
equally important question is “how” they interact with each other.  Clearly the interaction 
between activators and coactivators is not as simple as the North and South poles of two magnets. 
The multispecificity and multifunctionality of these proteins hint at a much more nuanced and 
complicated mechanism. For one thing, activators interact with coactivators and suppressors with 
a wide range of binding affinity at the same interaction site. For example, Gal4 TAD binds to its 
suppressor Gal80 with low nanomolar affinity
77
 whereas the same Gal4 TAD binds to Med15 
(Gal11) with a KD of 0.1 μM.
78
 The KIX domain of the mammalian coactivator CREB Binding 
Protein (CBP) binds to a FOXO3a TAD with an approximately 100 μM dissociation rate 
constant
79
 while the TAD of the phosphorylated kinase inducible domain (pKID) of CREB binds 
to the same KIX domain with a higher affinity (KD of  less than 1 μM).
80–82
 Furthermore, 
allostery plays an important part in coactivators that are multi-interface hub proteins, where one 
protein binding to the hub can elicit allosteric effects on a second distal binding site, thus 
enhancing or abrogating the binding of a different protein at the distal site.
83
 Evidence suggests 
that transcriptional activator-coactivator interactions are governed by complicated mechanisms 
12 
 
that likely involve conformational dynamics and interconversion between structured and 
disordered states.
61,73,84
 Deciphering these mechanisms will contribute to intelligently designing 
therapeutic strategies to correct disease-related aberrant transcriptional activator-coactivator 
interactions. The following section will discuss the progress made in this field and the questions 
that have yet to be addressed. 
 
D. Mechanisms of transcriptional activator-coactivator interactions 
D.1. In vitro techniques employed for studying the mechanism of transcription factor protein-
protein interactions 
Over the past few decades, many new techniques have emerged and have been employed in 
studying transcription factor protein-protein interactions. The following table is a brief overview 
of commonly used techniques. 
Table 1.1 Examples of techniques used in probing activator-coactivator interactions. 





affinity of two proteins 
by quantification of one 
protein that is bound to 













Used mostly in early studies of 
transcriptional activator-
coactivator interactions. 
Quantification by band intensity 






affinity, enthalpy and 
stoichiometry by 
monitoring heat change 









Can give useful thermodynamic 
information such as enthalpy. 
Does not require modification 
of the protein. 






binding affinity by 
monitoring the increase 
in polarity (decrease in 
tumbling rate i.e. 








Can be performed with small 
quantities in high throughput 
fashion. 
Only suitable when one 
component is much smaller than 
its binding partner, also requires 
a fluorescent probe 
13 
 




binding affinity by 
monitoring change in 
fluorescence intensity of 






Use of intrinsic fluorescent can 
avoid modifying protein. 
Relies on environmental 
changes to the fluorophore, 
which under some 
circumstances is not large 






binding affinity and 
conformational changes 
by monitoring acceptor 
fluorophore fluorescence 
intensity as excited 
donor fluorophore comes 




High sensitivity to distance, can 
be used as a “molecular ruler”. 
Is amenable to single molecule 
studies, and needs very small 
amount of material. 
Strict requirement of proximity 
of the donor and acceptor 
fluorophores. 
Known structural information is 
almost always required. 
Protein modification required. 
X-ray 
Crystallography 
Structure of protein 
complex can be 
compared to structure of 
















Can glean detailed structural 
information including side 
chain orientation. 
Proteins need to crystallize, 
need high concentration of 
material, the nature of crystal 
packing might result in artificial 




HSQC and 3D-NMR: 
Structure of protein 
complex can be 
compared to structure of 

















Amenable to proteins in 
solution, can capture more 
accurate average pose of PPI in 
more physiologically relevant 
conditions. 
Isotopic labeling of proteins is 
required, not amenable to large 
protein complexes (>50 kDa). A 




Besides static structural 
information can also 
detect domain and local 





By setting molecule in a 
non-equilibrium state 
and observing it return to 
the equilibrium state, can 
determine transient-state 














immobilized protein and 
flow-through protein 
causes change in light 
resonance from surface, 
can determine transient-
















Does not need large amounts of 
material, can obtain on-rate and 
off-rate data in same set of 
experiments. 
One component must be 






Real-time monitoring of 
spectroscopy change as 















Can observe interaction in 
solution, closer to physiological 
condition. Short dead-time, high 
time resolution. 
Often need larger volumes of 
protein.  
 
 While various techniques are being developed and optimized over the years, most techniques 
have certain shortcomings, and often times a combination of techniques are required to obtain a 
comprehensive picture of the mechanism of transcriptional activator-coactivator interactions. In 
addition, computational strategies such as molecular dynamics (MD) are often employed to 
simulate mechanisms that are difficult to monitor by existing techniques. There are also many 
techniques utilized to study protein-nucleic acid interactions and protein folding that are 
extremely useful and have not been employed to study transcriptional activator-coactivator 
interactions. These techniques include: fluorescent quench assays, single molecule FRET assays 
and ion-mobility mass spectrometry. New techniques and new combination of techniques are 
crucial in progressing further in our understanding of the transcriptional activator-coactivator 
interactions. 
 
D.2. Summary of activator-coactivator interaction mechanisms 
Recent studies on transcriptional activator-coactivator interactions have found several 
common aspects in the interaction mechanism. 
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One of the key features of transcriptional activator-coactivator interactions is that one or both 
components of the complex undergo significant conformational change. In many cases, the 
transcriptional activator TAD is intrinsically disordered and assumes a helical structure upon 
binding to a coactivator or suppressor, as is the case in pKID binding to KIX of CBP,
61
 Hif-1α 
binding to Taz1 of CBP,
105
 Gcn4 binding to Med15,
95
 Gal4 binding to Gal80,
106
 and VP16 
binding to hTAFII31.
107
  Some studies have found that this interaction follows an induced fit 
mechanism, as suggested in an SPR study on TADs Gal4 and VP16 binding to coactivators Swi1 
and TBP
102
 and a fluorescence stopped-flow study on the activation domain from the p160 
transcriptional coactivator for thyroid hormone and retinoid receptors (ACTR) binding to the 
nuclear coactivator binding domain (NCBD) of CBP.
103
 A more comprehensive view suggested 
by many other studies is that this interaction is a combination of both induced fit and 
conformational selection. This is often referred to as a coupled binding and folding mechanism 
where both the activator and the coactivator undergo conformational change upon binding 
(Figure 1.8).
108–110
 Examples as followed include NMR relaxation dispersion studies on the 
phosphorylated kinase inducible domain (pKID) of CREB binding to KIX domain of CBP
61
 and 
the ANC1 homology domain (AHD) of AF9 binding to elongation factor AF4.
111
 In most of the 
recent studies, the interaction is observed to undergo at least two steps: a fast association step 
and a slower transition step.
61,102,112,113
 Chapter 2 and Chapter 4 of this dissertation focus on this 
aspect. All of these previous studies have used isolated peptides as TADs. As the native state of 
transcriptional activators is a DBD-TAD modular construct that is also bound to DNA, using this 
simplified TAD peptide in interaction studies might not correctly reflect the kinetics of activator-
coactivator interactions. Chapter 2 addresses this issue by studying the interactions between a 






Figure 1.8 Schematic of coupled binding and folding, where the mechanism is a combination of 
induced folding and conformational selection. Figure modified from Wright et al, 2009.
114
 
Another interesting feature found in several transcriptional activator-coactivator interactions 
is that there can be more than one conformation or binding mode, which possibly contributes to 
the multispecificity of these species. For example, NCBD of CBP assumes different 
conformations when it binds to either ACTR or IRF3 (Figure 1.9a),
115
 the two TADs of 
FOXO3a can bind to either one of the two separate binding sites on the KIX domain of CBP with 
comparable affinity,
79
 and  Gcn4 has been shown to bind to Med15 in multiple poses, forming a 




Figure 1.9 a) Overlay of the NCBD of CBP in the free (purple, 1JJS), IRF3-bound (white blue, 
1ZOQ) and ACTR-bound (light yellow, 1KBH) conformations show significant variations. b) Three 
orientations of Gcn4-cAD (purple) binding to ABD1 of Med15 (gray) from ensemble of NMR 
solution structures (1LPB). Adapted from Brzovic et al, 2011.
95
 N-terminals are colored in cyan.   
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 There is also evidence that the entire domains do not contribute equally in binding 
interactions. Key regions can be more structured than their neighbors and nucleate the coupled 
binding and folding upon interaction with its binding partners.
116
 Also the side chains of specific 
residues can be extremely flexible and undergo a large axis of rotation upon the binding 
interaction, forming key electrostatic or hydrophobic interactions that nucleate the binding.
115,117–
120
 The work in Chapter 3 will exemplify such points. 
 
E. Small molecules as modulators of the transcriptional PPI network 
E.1. Targeting transcriptional activator-coactivator interactions with small molecules 
 One of the ultimate goals of understanding the mechanism of transcriptional activator-
coactivator interactions is to enable guided design of small molecule regulators of transcription. 
As protein-protein interactions usually consist of shallow, large interfaces, targeting this 
interface can be challenging.
46
 Understanding the underlying mechanism of these interactions 
can enable more accurate identification of small molecule modulators. Small molecules can be 
applied therapeutically for treating diseases that involve malfunction of transcriptional activator-
coactivator interactions. These therapeutic modulators can act by various modes of function: they 
can inhibit an over-regulated interaction, mimic an abrogated interaction or stabilize a weakened 
interaction.
121–124
 Another extremely useful function of small molecule modulators is their use as 
a mechanistic probe. There are still many unknown aspects of transcription. The ability to 
selectively inhibit a certain interaction and observe the resulting consequences will enable 
researchers to elucidate the related transcriptional pathways and mechanisms. This is especially 
advantageous when a single transcription factor interacts with multiple binding partners. Instead 
of genetically knocking down or knocking out the expression of an entire protein, it may be 
18 
 
possible for specific small molecule modulators to finely control only one interaction, hence 
pinpointing the target pathway that is studied. Outlined in Chapter 3 and Chapter 4 are studies on 
transcription factors in the context of small molecule modulators. 
 
E.2. Examples of small molecule modulators of activator-cofactor interactions 
 Many small molecule inhibitors of activator-coactivator have emerged in the past decade or 
so due to high demand of modulators in this crucial pathway. Especially remarkable are the 
plethora of small molecule inhibitors identified for the p53-MDM2 interaction, which has served 
as a model system to study with both experimentally and as a data training set to use in 
computational studies and predictions for small molecule inhibitors of PPIs.
121,125
 Below is a 
table outlining a few examples of these inhibitors. 














KD = 0.046 
μM 
 






KD = 0.4 nM 
 








IC50 = 0.14 
μM 







KD = 0.040 
μM 
 
IC50 = 0.10 
μM 






IC50 = 8 μM 
 





β-catenin-Tcf4 KD = 0.45 μM 






Ki ≈ 90 μM 
 
KD =115 μM 












MLL-KIX(CBP) KD = 38 μM 









IC50 = 17 μM 
 
MLL site 
IC50 = 34 μM 
Majmudar, C. 
Y., Højfeldt, J. 









IC50 = 25 μM 
 
MLL site 
IC50 = 17 μM 
Majmudar, C. 
Y., Højfeldt, J. 





While some small molecules are able to inhibit certain protein-protein interaction with high 
affinity, the majority of protein-protein interactions between transcriptional activators and 
coactivators still lack tight, specific small molecule modulators.
46
 Thus the work in this 
dissertation is focused on eludicating the mechanisms of these interactions to better design small 
molecule modulators. 
 
F. Thesis summary 
In this dissertation, I will describe the studies of the conformational and kinetic mechanism 
of transcriptional activator-coactivator interactions by focusing on two prototypical in vitro 
systems: the coactivator Med15 and activators Gal4, VP16 and Gcn4 (Chapter 2 and Appendix); 
21 
 
and the more conformationally defined KIX domain of coactivator CBP with activators MLL 
and pKID (Chapter 3 and Chapter 4). Additionally, the effects of a covalently tethered small 
molecule inhibitor of one binding site of KIX will be examined in the context of the stability of 
KIX and allosteric effects of its binding properties to activators at the opposite binding site. In 
Chapter 2, the transient-state kinetics mechanism of the interactions between Med15 and Gal4, 
VP16 and Gnc4 will be dissected by fluorescence stopped-flow. In Chapter 3, the conformational 
effect of a covalently tethered small molecule inhibitor on the KIX domain in CBP/p300 will be 
examined by biochemical and molecular dynamics methods and structural techniques such as 
solution protein NMR and X-ray crystallography. In Chapter 4, the kinetics and allosteric effect 
of a covalently tethered small molecule inhibitor on the KIX domain in CBP/p300 will be 
examined using fluorescence stopped-flow and other biochemical methods.  In summary, this 
dissertation seeks to shed new light on the mechanism of transcriptional activator-coactivator 
interactions by both conformational and kinetic studies. The results can provide insight into 
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Chapter 2 Kinetic Characterization of a Transcriptional 
Coactivator (Med15) in Complex with Transcriptional 





Several lines of evidence suggest that the prototypical amphipathic transcriptional activators 
Gal4, Gcn4 and VP16 interact with the key coactivator Med15 (Gal11) during transcription 
initiation, despite little sequence homology amongst the activators. Recent crosslinking data 
further reveal that at least two of the activators utilize the same binding surface within Med15 for 
transcriptional activation, yet activate transcription to quite different levels.
1
 The mechanism of 
these activator-coactivator interaction are poorly understood. However as they play an important 
part in the transcription pathway, knowing the mechanism of interaction would provide insight 
into designing small molecule modulators of activator-coactivator complexes to act as functional 
probes or even potential therapeutics. Hence this chapter describes a kinetic approach to dissect 
the activator-coactivator interaction mechanism. To assess if these three activators use a shared 
binding mechanism for Med15 recruitment, we characterized the thermodynamics and kinetics of 
Med15•activator•DNA complex formation by fluorescence titration and stopped-flow 
techniques. Combination of each DNA•activator complex with Med15 produces bi-phasic time-
                                                 
1
 This was a collaboration with Dr. Amberlyn M. Wands and data obtained by her is explicitly labeled within the 
chapter. The contents of this chapter are adapted and reproduced from a published article: Wands, A. M., Wang, N., 







 This is consistent with a minimal, two-step binding mechanism comprised of a 
bimolecular association step followed by a conformational change step of the 
Med15•activator•DNA complex. Furthermore, the equilibrium constant for the conformational 
change (K2) correlates with the ability of an activator to stimulate transcription. VP16, the most 
potent of the activators, has the largest value of K2 while the least potent, Gcn4, has the smallest 
value. This correlation is consistent with a model in which transcriptional activation is regulated 
at least in part by the rearrangement of the Med15•activator•DNA ternary complex. These results 
are the first detailed kinetic characterization of the transcriptional activation machinery and 
provide a framework for the future design of potent transcriptional modulators 
 
B. Background  
The unique transcriptional signatures associated with human disease have spurred enormous 
efforts towards the discovery of artificial transcriptional regulators.
3–6
 However, these efforts are 
hampered by an incomplete understanding of the mechanism utilized by transcriptional 
activators to interact with and recruit the transcriptional machinery to a gene promoter (Figure 
2.1a).
7
  What is known is that most activators have modular architecture, consisting minimally of 
a DNA binding domain (DBD) and a transcriptional activation domain (TAD),
8,9
 and that they 
activate transcription by physically recruiting transcriptional coactivators and the preinitiation 
complex to the promoter site of a gene.
10,11
 One domain of the activator, the transcriptional 
activation domain or TAD, carries out this process, interacting with a variety of coactivators that 
remodel chromatin and mediate assembly of the pre-initiation complex; these interactions 






Figure 2.1 a) Schematic of a transcriptional activator localized upstream of a gene promoter 
through a DNA-binding domain (DBD) (blue circle) which is poised for recruitment of the 
transcriptional machinery through interaction with the transcriptional activation domain (TAD) (red 
square). b) Primary amino acid sequences of the amphipathic TADs used in this study.  
 
B.1. Transcriptional activation domains (TADs) VP16, Gal4 and Gcn4 
Perhaps the three best-characterized transcriptional activation domains are those of VP16, 
Gal4 and Gcn4. They are mainly characterized in terms of their seqeunces, the proteins they 
target and basic determination of their affinity with their targets. These activators are members of 
the largest class of activators, the amphipathic class, characterized by interspersed polar and 
hydrophobic amino acid residues in their TADs (Figure 2.1b).  
 
Figure 2.2 a) Structure of VP16C (red) binding to the Tfb1 subunit of TFIIH (gray) (PDB: 2K2U). 
b) Structure of Gal4 DBD (1-100) bound to DNA, the two monomers that form a homodimer are 
depicted in light and dark green, and the Zn molecules in the Zn2Cys6 clusters depicted as purple 





VP16: The herpes simplex virus (HSV) virion protein 16 (VP16) is a transcriptional activator 
that regulates transcription of viral genes within an infected mammalian host cell, thus doing so 
through the formation of protein-protein interactions with endogenous host transcription 
factors.
12
 The C-terminal residues (residues 412-490) of the 490-residue VP16 protein have been 
identified as the transcriptional activation domain,
13
 which binds to many proteins involved in 
the transcriptional machinery, including TBP, TFIIA, TFIIB, TFIIH, hTAFII31, dTAFII40, the 
human cofactor PC4, CBP, p300
14
 and Med15 of the Mediator complex.
1,15
 The VP16 TAD is 
further dissected into two separate activation subdomains, the amino subdomain (VP16N: 
residues 412-456) and the carboxyl subdomain (VP16C: residues 456-490, used in this study).
16
 
Similar to many amphipathic transcriptional activators, the VP16 TAD is intrinsically disordered 
and has little to no secondary structure in its free state, while upon binding to its various partners 
the TAD assumes an α-helical structure.
14,17–19
 Despite being extensively studied and utilized as 
a model transcriptional activator, only recently has any high-resolution structural information 
been obtained on this domain, in which an NMR structure of VP16C in complex with the Tfb1 




Gal4: Gal4 is a yeast transcriptional activator from Saccharomyces cerevisiae that is involved 
in the regulation of galactose metabolism. It has also been shown to regulate transcription in 
other organisms such as Drosophila
21
 and mammalian cells.
22
 From as early as the 1980s, Gal4 
has been studied extensively as a model transcriptional activator.
23
 As of present day, both the 
DNA-binding properties of the Gal4 DBD
24
 and the coactivators/transcription factors recruited 
by Gal4 TADs are relatively well-defined.
25–27
 Notably, the structure of the Gal4 DBD (residues 
1-100,  used in this study) in complex with DNA is available, depicting a homodimer of 
32 
 
intertwined helical bundles binding to DNA via two Zn2Cys6 clusters.
24
 (Figure 2.2b) 
Furthermore, truncation studies on the ability of Gal4 to activate transcription have also 
identified a TAD region at the C-terminus of Gal4 that retains most of its activity,
28,29
 and this 
region (residues 840-881, used in this study) has been used as a minimal TAD for further 
studies.
30,31
 Studies suggest the Gal4 TAD is an unstructured domain that assumes secondary 
structure upon binding to coactivators or suppressors.
32
 To date, the only structural information 
of the Gal4 TAD is a 20-residue peptide (854-874) bound to its suppressor protein Gal80 in a 
loop form.
33
  This further demonstrates the difficulty of obtaining detailed structures of a 
disordered TAD. 
Gcn4: Gcn4 is a yeast transcriptional activator from Saccharomyces cerevisiae that regulates 
amino acid synthesis and consumption under amino acid starvation circumstances.
34
 It is a 281-
residue transcriptional activator including a C-terminal DBD and two tandem N-terminal 
TADs.
35,36
 The DNA binding domain binds to DNA via a leucine zipper motif, the structure of 
which has been studied extensively.
37–40
 The two N-terminal TADs are structurally independent, 
and are deemed the N-terminal TAD (residues 1-100) and the central TAD (residues 101-134, 
used in this study).
41,42
 Site-directed crosslinking studies have shown Gcn4 to interact with the 
Tra1, Med15/Gal11, and Taf12 subunits of the transcriptional gene regulation complexes SAGA, 
NuA4, Mediator, and TFIID.
43,44
 Additionally, extensive work has been done focusing on the 
binding properties of both Gcn4 TADs to the Med15/Gal11 subunit of Mediator.
1,42,45,46
 An 
NMR study has revealed that the Gcn4 central TAD (101-134) is intrinsically disordered when 






There is considerable evidence that, despite little sequence and structural homology, these 
TADs share key mechanistic features, including a functionally important binding interaction with 
the coactivator Med15(Gal11).
27,43,44,47,48
 Indeed, Gal4 and Gcn4 were recently shown to interact 
with the same binding site in the amino-terminus of Med15.
1
 Despite these similarities, the 
activators stimulate transcription to differing levels, with VP16-derived activators being the most 
potent and Gcn4 the least (see Results section Figure 2.7). The intrinsically disordered nature of 
these TADs hinder structural studies. Thus, we elected to carry out kinetics studies on the 
mechanism of these activator-coactivator interactions. 
 
B.2. Transcriptional coactivator Med15 (Gal11) 
The transcriptional coactivator Med15 (Gal11) is a subunit of the Mediator protein complex, 
which functions as a general transcriptional regulator of RNA Pol II transcription to stimulate 
basal transcription up to ten-fold.
49,50
 Originally identified as playing an essential role in yeast 
transcription,
51
 the Mediator complex has homologs in higher organisms such as murine and 
human.
52
 It is a large complex (1.2 Mda) consisting of ~ 20 subunits, and is further dissected into 
three subdomains, termed the “head”, “middle” and “tail” modules (Figure 2.3a).
52
 Biochemical 
and structural studies have shown that the Mediator complex is in direct contact with RNA 
polymerase II at all three of its modules.
50,51
Med15 resides in the “tail module” of the Mediator 
complex, this module is linked to the regulation of SAGA-dependent and TATA-containing 
genes in yeast.
53
 To this end, in vivo and in vitro experiments have identified several 
transcriptional activators that bind to Med15, including VP16, Gal4, Gcn4 and Oaf1.
47,54,55
 
Med15 is a 1081-residue protein, yet several domains have been dissected as activator binding 
domains (Figure 2.3b). 
1,45
 In particular, the N-terminal residues (~300) have been identified to 
34 
 
be responsible for the majority of binding interactions with the TADs of VP16, Gal4 and Gcn4. 
Thus, Med15 (1-345) has been used in this study.
1
 Limited structural information is known of 
Med15. This includes an NMR structure of the N-terminal KIX domain (residues 6-90), of which 
there are homologous domains in coactivators Arc105 and CREB Binding Protein (CBP),
56,57
 





Figure 2.3 a) Schematic of Mediator complex based on the electron microscopy structure and the 
projected subunits in each module. Figure from Chadick et al, 2005 
58
. b) Schematic of Med15 and 
various activator binding domains, the TADs binding to each domain are depicted on top of the 
graph. Structures of the KIX domain (PDB ID: 2K0N) and the Activator Binding Domain 1 (ABD1, 
PDB ID: 2LPB) shown. 
 
B.3. Controversy in kinetic models of activator-coactivator interactions  
Historically, comparisons of activator-coactivator interactions have centered on equilibrium 
binding measurements (apparent affinities) but these values are not a uniformly good predictor of 
function.
59–62
 Transcription is initiated through a series of coupled binding equilibria and thus a 
comparison of the kinetic and thermodynamic constants describing the individual steps of 
activator•coactivator complex formation should be more revealing of activator potency.   
35 
 
However, efforts to kinetically characterize these interactions have produced conflicting models 
for the mechanism of complex formation.
63–65
 In one example,
63
 the interaction between the TAD 
of NF-κB p65 and various coactivators was observed to be a single-step binding event, consistent 
with a simple co-localization function of the transcriptional activation domain. In another study, 
however, a two-step binding sequence was observed between the TAD of c-Myc and the 
coactivator TATA-binding protein (TBP),
64
 suggesting that a conformational change in one or 
both of the partners may contribute to the function of the activator. In both of these examples, the 
time resolution of the experiment was within the seconds’ range, limiting the ability to detect 
rapid changes happening in the early stages of the interaction.  An additional complication is that 
the kinetic studies to date have not examined activator-coactivator interactions under conditions 
where the activator is bound to DNA. This is important because,under physiological conditions, 
activators are always bound to their DNA recognition site, indicating that DNA-binding must 
play an important role in the process. 
 
B.4. Stopped-flow technique utilized in characterizing transient-state kinetics 
The technique of stopped-flow has been utilized in studying various biochemical interactions, 
for example: monitoring enzyme activity by absorbance of enzyme cofactors;
66
 monitoring 
protein-protein interactions by fluorescence;
67,68
 monitoring protein folding by circular 
dichroism;
69
 and monitoring protein folding by Fourier transform infrared (FT-IR) spectroscopy. 
The stopped-flow apparatus enables rapid mixing of two species and observation of change in 
real-time (Figure 2.4). Solutions of two reaction species are first placed into separate syringes. 
Once the driving motor presses both syringes down at the same time, equal amounts of solution 
are rapidly mixed in the mixer, which then enters the observation cell and replaces the existing 
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solution with freshly mixed solution. Spent solution that is pushed from the observation cell by 
fresh solution entering the stop syringe which causes the plunger to move forward and trigger 
data collection as well as stop the flow of the solutions. As a means of detection, changes in 
optical properties of the reaction mixture is monitored in the observation cell over real time 
(absorbance, fluorescence, light scattering, turbidity, fluorescence anisotropy etc.).  The time 
period from the solutions entering the mixer to arriving at the observation cell is called the “dead 
time”, which is where one cannot observe changes in the mixture. In modern stopped-flow 
devices, the dead time is as low as 2 milliseconds; hence one is able to monitor fairly fast 
reactions. 
 
Figure 2.4 Schematic of an average stopped-flow setup. The figure on the right is a typical signal 
output of a stopped-flow trace. 
 
The common experimental methods used to study the kinetics of protein-protein interactions 
include NMR relaxation dispersion, stopped-flow and surface plasmon resonance (SPR).
70
 NMR 
relaxation dispersion requires relatively high concentrations of isotopically labeled protein; 
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hence this method was not utilized in this project due to the limitations of solubility of the 
studied proteins. SPR requires immobilization of one of the binding components on a charged 
surface, and direct comparisons of association rate constants for a number of protein-protein 
complexes showed that SPR data may provide different transient-state kinetic values from those 
obtained in solution.
71,72
 Thus we elected to use the stopped-flow technique as no components 
are immobilized, which is a closer approximation of physiological conditions. 
The advantages of using the stopped-flow technique to study transient state kinetics include 
short dead time, rapid mixing, small sample volume needed for each reading, and the fact that all 
components of the interaction can be free in solution. For the above reasons, stopped-flow was 
the technique chosen in this chapter to dissect the mechanism of activator-coactivator 
interactions.   
 
C. Experimental Design 
C.1. Gal4 DBD-VP16, Gal4 and Gcn4 TAD fusion proteins as transcriptional activators 
Many transcriptional activators are modular, thus the DBD of one activator can be 
interchanged onto the TAD of a different activator, and this fused activator will bind to the DNA 




In our experimental design, each TAD is characterized in the context of a DNA-bound 
activator to mimic its presentation at a gene promoter. For this purpose, the well-studied Gal4 (1-
100) DNA-binding domain (DBD) fused to the TADs of Gal4 (residues 840-881), Gcn4 
(residues 107-144), and VP16 (residues 456-490) are expressed and purified from bacteria. Each 
DBD-TAD fusion protein exhibits an identical binding affinity (Kd =15 ± 5 nM) for a 
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fluorescently labeled consensus DNA binding site composed of two half sites, as determined 
through fluorescence polarization experiments (Figure 2.5);
2
 these Kd values are consistent with 
those previously reported for Gal4(1-100).
24
 Thus, the DNA binding function is independent of 




Figure 2.5 Dissociation constants of activators for DNA.  A constant 1 nM concentration of the 5’-
fluorescein-labeled duplex DNA was incubated with varying concentrations of Gal4(1-100)-TAD 
for 30 min at room temperature and the resultant polarization values at each protein concentration 
were obtained on a Beacon 2000 instrument (Pan Vera Corp).  Each value is the average of three 
independent experiments with the indicated error (standard deviation). This data was obtained by Dr. 
Amberlyn M. Wands. 
 
 
                                                 
2
 This section of work was performed by Dr. Amberlyn M Wands. 
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C.2. Solubility tags for recombinant protein expression 
Although transcriptional activators and Med15 lacking a solubility tag can be expressed and 
isolated, we observed that the propensity of these constructs to aggregate rendered them 
unsuitable for stopped-flow experiments, consistent with previous observations.
27,74
 Taking 
advantage of the ability of transcriptional activation domains to bind and function when fused to 
a wide variety of proteins, for example,
29,73,75–77
 we incorporated an MBP tag at the amino 
terminus of each activator to mitigate the aggregation propensity of the Gal4 DNA binding 
domain. Thus MBP-tagged activators and GST-tagged Med15 were expressed and isolated (See 
Methods section for complete details), and used in binding and kinetic experiments. Gel filtration 
experiments (Figure 2.6) indicate that GST-Med15 exists as a homodimer in solution over the 
range of concentrations used in the stopped-flow kinetic experiments. Thus, the indicated 
concentrations of Med15 represent that of the dimer. 
 
Figure 2.6 Analytical gel filtration data for GST-Med15 (1-345). a) Calibration curve for log 
(molecular weight) plotted against retention volume obtained with standards γ-globulin, ovalbumin 
and myoglobin. b) Chromatogram of 1.5 μM (based upon a monomer) GST-Med15 (red) compared 
to chromatogram of BSA (black) (monomer (66.4 kD) and dimer (132.8 kD)). 
 
C.3. Experimental setup of fluorescence stopped-flow assay 
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In the stopped-flow experiment, syringe A contained constant concentrations of fluorescein-
DNA•Gal4 (1-100)-TAD complexes and syringe B contained excess amount of varied 
concentrations of Med15 to achieve pseudo-first order conditions. 
To be consistent across different activators, fluorescein-labeled Gal4 binding site DNA (21 
bp oligomers) was utilized to act as the fluorescent probe in complex with Gal4 (1-100)-TAD 
fusion proteins. When the solutions are mixed in the stopped-flow experiments, there is a 25 nM 
concentration of DNA and 100 nM concentration of dimeric activator present (a 1:4 ratio).  From 
simulation studies performed in which the concentration of total DNA was set as a fixed 
parameter of 25 nM, and the Kd,app for activator binding to DNA is set as a fixed parameter of 15 
nM, and the total concentration of dimeric activator is varied, we estimate that the DNA is 84% 
bound at the concentrations we are using.  This was determined to be the optimal ratio of DNA: 
activator in order to maximize the amount of DNA in the bound form, minimize the amount of 
free activator, and still maintain pseudo-first order conditions for the stopped-flow experiments.  
It is from this preformed DNA•Activator complex that we detect a signal upon Med15 binding.  
 
D. Results 
D.1. Three activators show different levels of potency in S. cerevisiae 
Med15 resides in the multi-component Mediator complex thought to function as a conduit 
between DNA-bound transcriptional regulators and RNA polymerase II.
50,78,79
 Both genetic and 
biochemical studies suggest that Med15 is a key target of amphipathic activators.  Recent cross-
linking experiments localized functionally important binding interactions within the amino-
terminus of this protein.
1
 Furthermore, decreases in transcription are observed for Gal4, VP16 
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and Gcn4-derived activators in Med15 (1-345)-deleted strains compared to wild type yeast, as 
measured by -galactosidase assays (Figure 2.7).  
 
Figure 2.7 Activities of the Gal4 (1-100)-TAD activators (VP16 (456-490) > Gal4 (840-881) > 
Gcn4 (107-144)) in the presence of full-length Med15 (dark colored bars).  Deletion of the N-
terminal 345 amino acids of Med15 results in a loss of activity of all three activators (light colored 
bars).  Each β-galactosidase assay was performed at least in triplicate. The errors shown are 
standard deviation of the mean (SDOM). 
 
D.2. Binding affinity of activator•DNA complex to the coactivator Med15 
3
 
We next examined the affinity of the activator•DNA complex for the coactivator Med15 
under equilibrium conditions. Titration of micromolar concentrations of GST-tagged Med15(1-
345) 
27,74
 into a solution of pre-formed BODIPY®FL-DNA•Gal4(1-100)-TAD complex produces 
a hyperbolic increase in fluorescence (Figure 2.8). The three activators exhibit similar apparent 
                                                 
3
 This section of work was performed by Dr. Amberlyn M. Wands and is included here for completeness. 
42 
 
dissociation constants (Kd,app) with Med15 between 100 to 320 nM (Table 2.1); the affinity of the 
VP16- and Gal4-derived activators is ~2-fold higher than that of the Gcn4 activator. 
 
Figure 2.8 Dissociation constants of DNA-bound activators for Med15 (Gal11). A solution of 25 
nM 5’-BODIPY®FL-DNA•Gal4(1-100)-TAD complex was titrated with increasing amounts of 
GST-Med15(1-345) in DNA-binding buffer (final concentrations: 20 mM HEPES pH 7.5, 75 mM 
potassium acetate, 0.02 mM zinc sulfate, 4 mM magnesium acetate, 1 mM βME, 0.05 mM EDTA, 
10% glycerol, and 0.1 mg/mL BSA) at 25 °C  and the resultant fluorescence enhancement (λ ex = 502 
nm; λem > 510 nm) at each coactivator concentration (dimer concentration) was monitored on an 
Eclipse spectrofluorometer (Varian Corp).  Each value is the average of three independent 
measurements and the errors associated with these values are the standard deviation. This data was 
obtained by Dr. Amberlyn M. Wands. 
 







a. Assays were carried out in DNA-binding buffer (20 mM HEPES pH 7.5, 75 mM potassium 
acetate, 0.02 mM zinc sulfate, 4 mM magnesium acetate, 1 mM β-mercaptoethanol, 0.05 
mM EDTA, 10% glycerol, and 0.1 mg/mL BSA) at 25°C. 
b. Data fit according to a 1:1 binding interaction of DNA-bound activator to dimeric Med15. 
Each value is the average of three independent experiments with the indicated error 
(standard deviation). 
c. The value of kobs,2
max
 is extrapolated as described in Experimental methods. 
 




The association kinetics for formation of the BODIPY®FL-DNA•activator•Med15 complex 
                                                 
4























VP16 100 ± 20 23 ± 2 12.1 ± 0.7 4.6 
Gal4 143 ± 7 9.1 ± 0.8 3.6 ± 0.4 0.67 
Gcn4 320 ± 50 66 ± 8 26 ± 4 2.6 ± 0.4 
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were assessed by mixing Med15 with the BODIPY-DNA•activator complex in a stopped-flow 
fluorescence spectrometer under pseudo-first order conditions and measuring the time-dependent 
changes in fluorescence. Gal4, Gcn4, and VP16 all exhibit an increase in fluorescence over time 
at each Med15 concentration tested, producing time courses that are biphasic and best fit by a 
double exponential at both 25 ºC (Figure 2.9) and 16 ºC (Figure 2.10).  
  Analogous experiments performed by mixing DNA-bound Gal4 (1-100) lacking a TAD 
with Med15 or mixing the DNA•activator complexes with GST produced no increase in 
fluorescence over background (Figure 2.11), indicating that the fluorescence change reports only 
the Med15-TAD interaction.  
 
 
Figure 2.9 Biphasic kinetics observed for activator•DNA complex binding to Med15. Time-
dependent changes in fluorescence (λex = 502 nm; λem > 510 nm) after mixing either a) 5’-
BODIPY®FL-DNA•Gal4(1-100)- VP16(456-490), b) 5’-BODIPY®FL-DNA•Gal4(1-100)- 
Gal4(840-881), or c) 5’-BODIPY®FL-DNA•Gal4(1-100)- Gcn4(107-144) activator complex (25 
nM DNA and 100 nM DBD-TAD fusion protein after mixing) with an equal volume of dimeric 
GST-Med15 (0.5 μM with VP16; 0.625 μM with Gal4 and 0.75 μM with Gcn4 after mixing) in a 
stopped-flow apparatus in DNA-binding  buffer at 25 °C  (grey line). The red line superimposed on 
the time course is the best single exponential fit to the data, while the black line is the best fit of the 
sum of two exponentials to the data. Residuals for the single exponential fit ( red line) or double 
exponential fit (black line) to the time courses above reveal that a double exponential is the best fit 
to the data. Values for the first and second time domains are plotted with respect to the left and right 





Figure 2.10 a) Binding time course of 50 nM 5’-BODIPY®FL-labeled, double-stranded 
oligonucleotides pre-complexed to 200 nM dimeric MBP-tagged Gal4 (1-100)-TAD mixed with 
Med15 (0.375 μM after mixing) in a stopped-flow apparatus in DNA-binding buffer at 16 °C. The 
blue line superimposed on the time course is the best fit of the sum of one exponential to the data, 
while the red line is the best fit of the sum of two exponentials to the data. b) Residuals for the 
single exponential fit (blue line) or double exponential fit (red line) to the time course in a) reveals 





Figure 2.11 Negative control stopped-flow experiments. a) No fluorescence enhancement is observed 
in the time-course when 50 nM 5’-BODIPY®FL-labeled, double-stranded oligonucleotides pre-
complexed to 200 nM dimeric MBP-tagged Gal4 (1-100) is mixed with Med15 (0.375 μM after mixing) 
at 25 ºC. b) No fluorescence enhancement is observed in the time-course when 5’-BODIPY®FL-
DNA•Gal4 (1-100)-Gal4 (840-881) activator complex (5 nM after mixing) is mixed with GST (0.25 μM 
after mixing) at 25 ºC. This data was obtained by Dr. Amberlyn M. Wands. 
The observed rate for the faster phase (kobs,1) is linearly dependent on the Med15 
concentration for all three activator constructs with a positive slope reflecting an apparent 
























 suggesting that this step is the binding of Med15 to the 
activator•DNA complex.
5
 The observed rates for the slower phase (kobs,2) (Figure 2.12b) are 
dependent on the identity of the TAD (Figure 2.12b and Table 2.1) and have a modest 
dependence on the concentration of Med15. The higher errors in the rates are due to the smaller 
amplitude of this slower phase. Lowering the temperature to 16°C results in a more prominent 
slower phase with rates that are decreased 2-4 fold (Figure 2.10).    
                                                 
5
 To a first approximation, these values are identical.  Additionally, the occurrence of a rapid conformational change 
within the time-scale of this initial binding phase could contribute to the small differences in the apparent 





Figure 2.12 Plot of kobs,1 a) and kobs,2 b) of the activators VP16 (■), Gal4 (●) and Gcn4 (▲) against 
the concentration of Med15 (0.125 - 0.75 μM). The standard errors for both observed rates are 
indicated. The solid line in a) is a curve-fit to these data. The solid line in b) is simulated kobs,2 
according to Scheme A using the extrapolated kobs,2 max values of 4.6 s
-1
 (VP16), 0.67 s
-1
 (Gal4) and 
2.6 s
-1
 (Gcn4). Simulated kobs,2 values at each concentration of Med15 were obtained by fitting Eq. 
2.4 to the simulated traces of the time-dependent formation of [DNA•Activator•Med15] + 
[(DNA•Activator)*•Med15]. In these simulations, the microscopic rate constants k1 and k-1 (Table 
2.2), as well as calculated values for k2 and k-2, were constants (VP16: k2=3.2 s
-1











, all values are calculated within 20% 
propagated error).   
 
These biphasic binding kinetics suggest a minimal kinetic mechanism that requires a two-
step binding process. The fact that the rate of the slow phase is sensitive to temperature and does 
not exhibit a linear dependence on Med15 concentration (Figure 2.12 and Figure 2.10) is 
consistent with the occurrence of a unimolecular conformational change step that occurs either 
after or before the bimolecular binding step (Schemes A and B, respectively, in Figure 2.13).  
Additionally, the relative amplitudes of the two phases depend on the TAD of each activator 




Figure 2.13 Schematics of the two limiting binding models for DNA-bound activators interacting 
with Med15. In Scheme A, the conformational change occurs after an initial binding event, whereas 
in Scheme B, the DNA-bound activator undergoes a conformational change prior to associating with 
Med15. The pathway used by an activator may change depending upon the concentration(s) of the 
individual binding partners. 
 
 
Figure 2.14 Plot of the ratio of amplitude of the slow phase (amp2) relative to the amplitude of the 
fast phase (amp1) for all three activators VP16 (■), Gal4 (●) and Gcn4 (▲) against the concentration 
of Med15 (0.125 - 0.75 μM). 
 
D.4. Microscopic kinetic rate constants calculated for the two-step binding model. 
The full solutions to the rate equations describing the two limiting binding mechanisms 
shown in Figure 2.13 have been published elsewhere.
81
 The microscopic rate constants included 
in kobs,1 and kobs,2 can be approximated for each of the limiting pathways (Figure 2.13, Schemes 
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A and B) according to Equations 2.3-2.8 and Equations 2.9-2.14, respectively (see Experimental 
methods).
82
 Using these equations, the microscopic rate (k1, k-1) and equilibrium (K1) constants 
for Scheme A, the binding mechanism in which a conformational change occurs after the 
bimolecular collision step, were calculated from the experimentally obtained values presented in 
Table 2.1 for kon, kobs,1
(y-intercept) 
and the values of kobs,2
max
 extrapolated to saturating Med15 (see 
Experimental methods). Specifically, k1 is determined from the slope of kobs,1 versus Med15 




, and K1 is the ratio k1/k-1. The 
value of K2 was then calculated from Kd,app (Table 2.1) and K1. The results are
 
summarized in 
Table 2.2. The values for k2 and k-2 were also estimated (from kobs,2
max
 and K2) for use in 
simulation studies presented later.
6
 
Table 2.2 Calculated rate constants for binding model in Scheme A 










VP16 23 7.6 3.1 2.3 
Gal4 9.1 2.9 3.1 1.3 
Gcn4 66 24 2.8 0.12 
 
Similarly the microscopic rate and equilibrium constants for the binding mechanism 
presented in Scheme B, in which a conformational change occurs before the bimolecular 
collision step, are presented in the Table 2.3. 


























VP16 4.6 6.9 ± 0.8 23 ± 2 0.95 ± 0.3 24 ± 14 0.70 ± 0.05 
Gal4 0.67 2.7 ± 0.5 9 ± 1 0.26 ± 0.5 34 ± 40 0.25 ± 0.04 
Gcn4 2.6 ± 0.4 21 ± 5 66 ± 8 2.3 ± 2.9 29 ± 36 0.12 ± 0.03 
                                                 
6
 While k1 and k-1 are calculated directly from the kinetic data, to obtain k2 and k-2 one must use the Kd determined 
through equilibrium binding measurements (Figure 2) that were carried out under conditions that differ slightly. 
Experiments to directly measure the off rate (koff) in order to better define k2 and k-2 were unsuccessful due to 
aggregation propensities of the TADs at the high concentrations needed for these experiments. 
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D.5.Global kinetic simulation studies suggest that Med15 binding precedes the conformational 
change. 
The data from individual stopped 
flow experiments were globally 
analyzed using the KinTek Global 
Kinetic Explorer Program with either 
the Scheme A or Scheme B models. 
The values for k1 (Scheme A) or k4 
(Scheme B) were used as a constraint in 
these fits (Table 2.2 and Table 2.3). 
Scheme A provided a modest to 
significantly better fit to the 
experimental data relative to Scheme 
B.
7
 This suggests that a model in which 
the conformational change step occurs 
after the formation of the 
Med15•activator•DNA complex (Scheme A) is the more appropriate framework for describing 
this interaction.  
To examine whether the limiting kinetic models are sufficient to describe the data, the 
transient kinetic curves were simulated using the rate constants for Scheme A (calculated by 
Equations 2.3-2.8: k1 and k-1 (Table 2.2), as well as k2 and k-2) as fixed parameters, and allowing 
the change in fluorescence for each step to vary. The simulated curves agree well with the 
                                                 
7
 Goodness of fit was determined by Chi
2
/Degrees of Freedom (DoF) values. Chi
2
/DoF values for Scheme A: 
VP16:1.07; Gal4:1.06; Gcn4:1.07. Chi
2
/DoF values for Scheme B: VP16:1.14; Gal4:1.52; Gcn4:1.14. 
 




mixed with 0.625 μM dimeric GST-Med15 are overlaid 
with simulated traces (black line) based on Scheme A 
using Kintek Global kinetic explorer. The values for the 
microscopic rate constants k1 and k-1 (Table 2.2), as well 
as calculated values for k2 and k-2, were used as 














, all values are calculated within 20% 
propagated error.)  Experimental data and simulated 
traces reflect a change in fluorescence intensity. The 
three TADs are offset by 1.0 (VP16), 0.5 (Gal4) and 0 




experimental stopped-flow traces (Figure 2.15). In comparing the three activators, the traces 
show a decrease in amplitude of the slow phase relative to the fast phase (Figure 2.14) consistent 
with the decreasing value of K2.  
In summary, these simulations demonstrate that the data are best-described by a scheme in 
which the observed conformational change occurs after the DNA-bound activator associates with 
Med15 (Figure 2.13, Scheme A).
83–85
 Consistent with this mechanism, structural studies 
performed on the isolated TADs of Gal4 and VP16 have shown them to be mostly unstructured 
in the absence of their binding partners, but helical in the bound form 
18,86–88
 and this behavior is 





Here, for the first time, we report the transient kinetics of prototypical activator•DNA 
complexes interacting with the key coactivator Med15. Importantly, these data demonstrate that 
three distinct amphipathic activators interact with Med15 via a two-step binding mechanism that 
includes a conformational change. The limiting kinetic pathways for this two-step mechanism 
differ only in the order of the two steps (Scheme A and Scheme B, Figure 2.13).  While our 
kinetic data do not absolutely distinguish these mechanisms, Scheme A, in which a 
conformational change step occurs after the association step, is most consistent with the high 
value of the bimolecular rate constant, the simulation data, and previous data demonstrating the 
formation of helical structure in the isolated TADs of Gal4 and VP16 upon interaction with their 
binding partners.
18,86–88
 We therefore further analyze these data using this kinetic mechanism.  
A comparison of the measured rate and equilibrium constants determined for Scheme A 
reveals trends that provide insight into the differential activity of the three activators Gal4, Gcn4, 
and VP16. In general, the TAD activity correlates with a more favorable Kd,app for Med15 (VP16 
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> Gal4 > Gcn4) (Figure 2.16, Table 2.1). 
 
Figure 2.16 Comparison of the equilibrium constants (K1 and K2) for the binding mechanism 
presented in Scheme A. Values are normalized to the most potent activator, VP16. Activity values are 
obtained by in vivo β-gal assays. Error bars depict standard deviation (SD) of each averaged value. 
Analysis of the thermodynamics of the individual steps within the kinetic mechanism reveals 
that this correlation is governed not by the equilibrium constant for the initial bimolecular 
association step (K1), which is invariant among all three TADs, but by the value of the 
subsequent conformational change step (K2) (Figure 2.16). In particular, a greater value for K2 
(more favorable conformational change step) correlates with a more active TAD. To play an 
important role in regulating activation by varying the concentration of the active 
(DNA•activator)*•Med15 complex, the conformational change must be unfavorable for some or 
all of the TADs. Consistent with this model, for VP16, the equilibrium constant for the 
conformational change is moderately favorable (K2 = 2.3) indicating that at saturating Med15, 
more than 70% of the DNA•VP16•Med15 complex forms the active conformation. In contrast, 
the conformational change is unfavorable for Gcn4 (K2 = 0.12) indicating that only ~10% of the 
DNA•Gcn4•Med15 complex is in the active conformation. Although less well-defined by the 
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data, a similar trend is observed for kinetic partitioning between the conformational change and 
dissociation of Med15 (k2/k-1); the most active TAD, VP16, has the largest value of k2 and the 
largest partition ratio, indicating that the intermediate DNA•activator•Med15 complex undergoes 
the conformational change the fastest of the three activators and has the highest partition ratio to 
form the new conformer relative to dissociation. 
 
F. Conclusions 
In conjunction with structural evidence that isolated TADs of this class are intrinsically 
disordered and undergo structural enhancement upon interaction with a target protein 
8,92,93
 we 
hypothesize that the different degree of transient structure inherent to each TAD may play a role 
in the differences observed in the kinetics during the conformational change step to form the 
final DNA•activator•Med15 complexes (k2). For example, the faster conformational change 
observed for VP16 compared to that of Gal4 and Gcn4 may be attributed to the fact that residues 
472-479 within the isolated VP16 TAD have a propensity to form a relatively well-defined 
helix,
94
 although additional structural studies will be required to refine this model. Furthermore, 
it is important to note that although the current method of detection through an enhancement in 
fluorescence of a probe on the DNA limits our abilities to determine which component(s) within 
the complex is undergoing the conformational change, future studies in which the probes are 
placed at the TAD-target interface will provide additional details in this regard.  
Finally, the favorability of the conformational change (K2), which is encoded in the primary 
amino acid sequence of each TAD by the particular arrangement of the acidic, polar, and 
hydrophobic amino acid residues,
95
 may explain why three TADs that target the same protein via 
a shared binding mechanism can lead to differences in the assembly of the pre-initiation complex 
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and transcriptional output. Thus, the identification of artificial TADs with additional structural 
stability may lead to artificial activators with enhanced transcriptional activity. 
 
G. Experimental Methods 
Plasmid Construction 
Plasmids encoding MBP-tagged Gal4 (1-100) fused to different TADs and GST-tagged 
Med15 (1-345) were constructed and prepared by standard molecular cloning methods.  
Table 2.4:  Plasmids used in this study
 
Plasmid name Reference Function 
pGal4(1-100)-Gal4(840-881) 
96
 ARS/CEN yeast expression plasmid 
under the control of a β-actin promoter 
with a HIS
+









 ARS/CEN yeast expression plasmid 
under the control of a Med15 native 
promoter with a LEU
+







Expresses activators fused to the His6-









 Expresses Med15 fused to the GST 
solubility tag in E. coli 
 
-galactosidase Assays 
LS41ΔMed15 [JPY9::ZZ41, Mat his3Δ200 leu2Δ1 trp1Δ63 ura3-52 lys2Δ385 gal4 
URA::pZZ41 Med15::TRP] yeast was co-transformed with plasmids encoding each Gal4 (1-
100)-TAD fusion and a fragment of Med15.  The activity of each activator construct was 








Protein Expression and Purification 
His6-MBP-tagged activators: Expression of the activators fused to a His6-MBP tag was 
carried out in Rosetta2 (DE3) pLysS E. coli cells (Novagen) as previously described.
98
 
Maltose-binding protein (MBP) has been demonstrated to effectively enhance the solubility 
of aggregation-prone proteins;
99
 in addition, fusion of solubility tags to the N-terminus of the 
Gal4 DBD has been reported previously not to impact activator function.
77,100
 Briefly, 
cultures (50 mL) inoculated with single colonies were grown overnight at 37 °C (250 rpm) in 
Lennox L Broth (Research Products International) supplemented with ampicillin (100μg/mL) 
and chloramphenicol (34 μg/mL) before dilution (50-fold) into 8 x 50 mL cultures of Lennox 
L Broth supplemented with ampicillin (100 μg/mL). After an OD600 of 0.4 was reached, 
protein over-expression was induced with IPTG (final concentration 1 mM) in the presence 
of 20 μM ZnSO4 for 5 hours. Cells in 50 mL culture were pelleted by centrifugation, 
resuspended in 10 mL lysis buffer A (10 mM Tris, pH 8.0 at 4 °C, 500 mM NaCl, 10% 
glycerol (v/v), 10 mM β-ME, 0.1% Tween* 20 (v/v), and Roche Complete Protease Inhibitor 
Cocktail), then lysed using sonication. His-tagged protein was isolated by incubating cell 
lysate with 200 μL of Ni-NTA beads (Qiagen) for 1 hour at 4 °C, followed by washing 8 
times with 1 mL wash buffer A (20 mM Tris, pH 8.0 at 4 °C, 100 mM NaCl, 20% glycerol 
(v/v), 1 mM β-ME, 0.1% Tween* 20 (v/v), 30 mM imidazole). The protein was eluted from 
the beads by incubation at 4 ºC overnight with 1 mL elution buffer A (20 mM Tris pH 8.0 at 
4 °C, 100 mM NaCl, 20% glycerol (v/v), 250 mM imidazole). The protein solution was 
buffer exchanged into storage buffer A (20 mM HEPES, pH 7.5 at 4 °C, 200 mM NaCl, 10% 
glycerol (v/v), 1 mM β-ME, 1 mM EDTA, 20 μM ZnSO4) using a PD-10 column (GE 
Healthcare), and the protein concentration was measured using absorbance at 280 nm.  The 
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identity and purity (>90%) of the protein was verified by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE).  
GST-tagged Med15 (1-345): Expression of GST-Med15 (1-345) was carried out in Rosetta2 
(DE3) pLysS E. coli cells (Novagen). Glutathione S-transferase (GST) has been demonstrated to 
effectively enhance the solubility and stability of aggregation-prone proteins (8); in addition, 
fusion of GST to the N-terminus of Med15(Gal11) has been reported previously not to impact 
activator binding to this target protein.
1,27,74
 Briefly, cultures (50 mL) from single colonies were 
grown overnight at 37 °C (250 rpm) in Select APS Super Broth (Difco) supplemented with 
ampicillin (100μg/mL) and chloramphenicol (34 μg/mL) before dilution (100-fold) into 4 x 1 L 
of Select APS Super Broth supplemented with ampicillin (100 μg/mL). After an OD600 of 0.3 
was reached, the cultures were cooled for 45 min at 16 °C (150 rpm), and expression was 
induced with IPTG (final concentration 0.1 mM) for 5-6 hours at 250 rpm. Each cell pellet was 
resuspended in 25 mL lysis buffer B (100 mM PBS pH 7.4 (Pierce), 0.2% NP-40 Substitute 
(Fluka), 10% glycerol (v/v), 1 mM DTT and Roche Complete Protease Inhibitor Cocktail), lysed 
using sonication, and the GST-tagged protein was isolated using Glutathione Sepharose 4B (GE 
Healthcare). The cell lysate was incubated with 2 x 1 mL of glutathione beads for 1 hour at 4 °C. 
The beads were washed 6 times with 10 mL wash buffer B (100 mM PBS pH 7.4 (Pierce), 0.2% 
NP-40 Substitute (Fluka), 10% glycerol (v/v), 1 mM DTT), and the protein was eluted from the 
beads by incubation at 4 ºC overnight with 1 mL elution buffer B (50 mM Tris pH 8.0 at 4 °C, 
0.015 M reduced glutathione, 0.1% NP-40 Substitute). Additional protein was eluted from the 
column by twice incubating the beads with elution buffer for 1 hour at 4 °C.  The protein 
samples were combined and concentrated using a Centriprep 10K centrifugal filter device before 
buffer exchange into storage buffer B (10 mM PBS pH 7.4 (Pierce), 10% glycerol (v/v), 0.01% 
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NP-40 Substitute, 1 mM DTT) using a PD-10 column (GE Healthcare).  The protein was 
then concentrated using a Vivaspin 30K centrifugal filter device, and the protein 
concentration was measured using absorbance at 280 nm.  The identity and purity (>85%) of 
the protein was verified by reducing SDS-PAGE with appropriate molecular weight 
standards. 
 
Analytical Gel Filtration 
Analytical gel filtration was performed to determine the oligomeric state of GST-Med15 
(1-345) over the concentration range used in the fluorescence stopped-flow kinetic 
experiments described below. A final concentration of 1.5 μM and 0.5 μM (based on 
monomer concentrations) of GST-Med15 (1-345) was run through a Superose 6 gel filtration 
column equilibrated with DNA-binding buffer (20 mM HEPES pH 7.5, 75 mM potassium 
acetate, 0.02 mM zinc sulfate, 4 mM magnesium acetate, 1 mM β-mercaptoethanol, 0.05 mM 
EDTA, 10% glycerol, and 0.1 mg/mL BSA).
27
 At the highest concentration of GST-Med15 
(1-345) tested (1.5 µM), only a single peak eluted as detected by UV (280 nm), with a 
projected molecular weight of 114 kDa as determined from molecular weight standards 
(Figure 2.6). These data are consistent with a dimeric state of GST-Med15 (1-345) (monomer 
= 62.5kD, dimer = 125 kDa). This same species was the only species observed at the lowest 
concentration tested (0.5 µM) as determined by a western blot probing for GST on eluted 
fractions (Figure 2.6). 
 
Fluorescence Polarization Assays to Measure DNA Affinity to Transcriptional Activators 
The 20 bp oligonucleotide 5'-TCC GGA GGA CTG TCC TCC GG-3’ (26) labeled at the 
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5’end with fluorescein or BODIPY®FL was purchased from Invitrogen. The fluorescently 
labeled oligonucleotide was then annealed with an unlabeled complementary oligonucleotide (5’-
GCC GGA GGA CAG TCC TCC GG-3') in annealing buffer (10 mM HEPES pH 7.5, 150 mM 
NaCl) by heat denaturation for 7 min at 95 ºC, followed by cooling at room temperature for 30 
min and 4 ºC for 30 min.  
Annealed fluorescein-labeled oligonucleotide (45 μM) was diluted in DNA-binding buffer 
(20 mM HEPES pH 7.5, 75 mM potassium acetate, 0.02 mM zinc sulfate, 4 mM magnesium 
acetate, 1 mM β-mercaptoethanol (βME), 0.05 mM EDTA, 10% glycerol, and 0.1 mg/mL BSA) 
to a concentration of 1.25 nM. Then 200 µL of the DNA solution was added to a series of 50 µL 
solutions of varying activator concentrations in storage buffer A (20 mM HEPES, pH 7.5 at 4 °C, 
200 mM NaCl, 10% glycerol (v/v), 1 mM βME, 1 mM EDTA, 20 μM ZnSO4) to obtain the final 
concentrations of up to 0.5 μM. The samples were incubated for 30 min at room temperature 
before the degree of fluorescence polarization was measured (Beacon 2000, Pan Vera Corp). A 
binding isotherm that accounts for ligand depletion 
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 (assuming a 1:1 binding model of dimeric 
activator to duplex DNA) was fit to the observed mP values as a function of activator to obtain 
the apparent equilibrium dissociation constant, Kd: 
 
where “a” and “x” are the total concentrations of duplex DNA and dimeric activator, 
respectively, “y” is the observed polarization at any activator concentration, “b” is the maximum 
observed polarization value, and “c” is the minimum observed polarization value. Each data 
point in Figure 2.5 is an average of three independent experiments with the indicated error 




Fluorescence Titration Assays to Measure Med15 Affinity to Transcriptional Activators 
GST-Med15(1-345) in storage buffer B (10 mM phosphate-buffered saline pH 7.4 (Pierce), 
10% glycerol (v/v), 0.01% NP-40 substitute, 1 mM dithiothreitol (DTT)) was titrated (without 
exceeding a 5% volume increase) into the following solution to obtain the final Med15 
concentrations indicated in Figure 2: 25 nM 5’-BODIPY®FL-labeled, double-stranded 
oligonucleotide pre-incubated with 100 nM dimeric activator in DNA-binding buffer. Under 
these conditions 84% of the DNA is estimated to be complexed with activator, as calculated 
using Equation 2.1. The fluorescence intensity of BODIPY®FL was monitored on an Eclipse 
spectrofluorometer (Varian Corp) (λex = 500 nm, λem = 512 nm; 5 nm band pass). The 
fluorescence intensity (Fi) was corrected for dilution effects and background fluorescence from 
the DNA•activator complex (F0), such that ΔF = Fi-F0. The observed fluorescence fraction 
increase, ΔF/F0, was plotted as a function of Med15 concentration, and a binding isotherm that 
accounts for ligand depletion (Equation 2.1) (assuming a 1:1 binding model of DNA•activator 
complex to dimeric GST-Med15) was fit to the data using Origin 7.0 software to obtain the 
apparent equilibrium dissociation constant, Kd. The parameters “a” and “x” represent the total 
concentrations of DNA•activator complex and dimeric Med15, respectively, “y” is the observed 
fluorescence enhancement at any Med15 concentration, “b” is the maximum observed relative 
fluorescence enhancement value, and “c” is the minimum observed relative fluorescence 
enhancement value. Each data point in Figure 2.8 is an average of three independent experiments 
with the indicated error (standard deviation). 
 
Fluorescence Stopped-flow Kinetic Experiments 
Stopped-flow experiments were performed on a KinTek model SF-2001 stopped-flow 
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equipped with a 75W Xe arc lamp in two-syringe mode. 50 nM 5’-BODIPY®FL-labeled, 
double-stranded oligonucleotide pre-complexed to 200 nM dimeric MBP-tagged Gal4(DBD) 
fused to different TADs in DNA-binding buffer (25 nM and 100 nM after mixing) was mixed 
with an equal volume of GST-tagged Med15(1-345) (final concentration after mixing 0.125-0.75 
μM for homodimer) in DNA binding buffer at 25 °C. BODIPY®FL was excited at 502 nm and 
its emission was monitored at wavelengths > 510 nm using a long-pass filter (Corion). All 
kinetic traces reported are an average of four to six independent determinations. Sum of 
exponentials was fit to the transient kinetic time courses, F (t) as in Equation 2.2, to obtain the 
fluorescence amplitude (A) and the observed rate, kobs, for each exponential phase where F (0) is 
the initial fluorescence intensity, and t, time: 
 
Two control experiments were performed to ensure that the fluorescence changes are from a  
Med15-TAD interaction: 50 nM 5’-BODIPY®FL-labeled, double-stranded oligonucleotides pre-
complexed to 200 nM dimeric MBP-tagged Gal4(1-100) was mixed with Med15 (0.375 μM after 
mixing) at 25 ºC, and 5’-BODIPY®FL-DNA•Gal4(1-100)-Gal4(840-881) activator complex (5 
nM after mixing) was mixed with dimeric GST (0.25 μM after mixing) at 25 ºC. No time-
dependent fluorescence enhancement was observed in either experiment (Figure 2.11). 
Analysis of the time courses was performed using Kintek software, and the reported errors 
are the asymptotic standard errors. The dependence of the observed rates on Med15 
concentration was analyzed using GraphPad Prism 4.0 software. Each kinetic constant reported 






Calculation of the Microscopic Kinetic Rate and Equilibrium Constants for the Two-step 
Binding Models 
Approximate solutions for kobs,1 and kobs,2
max
  in terms of the microscopic rate and equilibrium 
constants can be obtained from Equations 2.3 & 2.4 for Scheme A and Equations 2.9 & 2.10 
for Scheme B, respectively.
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 These equations are approximations from the full solutions 






Equations used to calculate the microscopic rate and equilibrium constants, according to 
the binding model presented in Scheme B, are as follows: 
  
As described in the text, the experimentally obtained values for Kd,app, kon, kobs,1
(y-intercept) 
(summarized in Table 2.1) were used to calculate the microscopic rate constants for the fast 














and Equations 2.9-2.14 for Scheme B.  The value of  kobs,2
max
  used in these calculations was 
extrapolated to saturating Med15 concentration, as outlined in the subsequent section. The 
calculated values for the microscopic constants for Scheme A (k1, k-1, K1 and K2) are summarized 
in Table 2.2. The calculated values for the microscopic constants for Scheme B (k4, k-4, K3 and 
K4) are summarized in Table 2.3.  
 
KinTek Global Kinetic Explorer Analysis 
Experimental fluorescence traces were fit with KinTek Global Kinetic Explorer
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  based on 
the Scheme A and Scheme B models (Figure 2.13) including parameters describing the 
fluorescence change in each step.  The value of k1 (k4 in the case of Scheme B) was calculated 
from experimental data using Equation 2.3 (Equation 2.9 in the case of Scheme B) and served as 
a fixed constraint in the simulated fitting process. Values for Med15 concentrations and 
BODIPY-DNA•activator complex concentrations were set as the experimental values.  
Due to the aggregation 
propensity of Med15 at higher 
concentrations, stopped-flow 
experiments were not carried out at 
saturating Med15 concentrations.  
To estimate the value of kobs,2
max
, 
kinetic traces of the concentrations 
of the intermediates were simulated 
(KinTek Global Explorer) at 
varying Med15 concentrations and kobs,2
max
 values.  The value of kobs,2
max
 that gave the best 
 
Figure 2.17 Plot of the amplitudes of the slow phase of 
the activators VP16 (■), Gal4 (●) and Gcn4 (▲) against 




description of the measured data is listed in Table 1 and used in subsequent calculations. In each 
case, the value of kobs,2
max
 increases ≤50% from the measured value at the highest [Med15]. The 
Med15 concentration dependence of kobs,2 is also consistent with the K1/2 value for the [Med15]-
dependence of the second phase amplitude (Figure 2.17). 
 Values for k2 and k-2 were also calculated using Equations 2.5 and 2.8:  
 
The calculated rate constants k1 and k-1 in Table 2.2, along with calculated values for k2 and k-
2 were used to simulate experimental traces based on the Scheme A model (Figure 2.13), 
allowing the change in fluorescence to vary for each step.  
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Chapter 3 Structural Characterization of Transcriptional 





Transcriptional coactivators are among the most conformationally malleable of proteins and 
contain binding surfaces that undergo rapid remodeling as complexes are formed with their 
cognate ligands.
1,2
 This plasticity is essential to their function, enabling recognition of an often 
diverse array of transcriptional activator sequences.
3,4
 Perhaps the best-studied example of this is 
the KIX domain of the coactivator CBP/p300, a small (90 amino acid) domain that is known to 
interact with >10 distinct amphipathic sequences at two distinct binding sites (Figure 3.1) in 
order to stimulate transcription at hundreds of genes,
5–9
 including those regulating hematopoiesis, 
memory formation and the inflammatory response.
10–12
 Not surprisingly, the malleability of this 
class of proteins renders them especially intractable to crystallographic characterization, either 
alone or in complex with their binding partners. In the case of the KIX domain, there are no 
crystal structures of either free protein or any complexed form. Here we demonstrate that a 
covalently linked small-molecule ligand of this conformationally dynamic protein enables, for 
the first time, a high resolution snapshot of the coactivator interacting with a ligand. This first 
crystal structure of KIX provides important insight to the side chain orientations of this domain 
                                                 
8
 The contents of this chapter are adapted and reproduced from a published article: Wang, N., Majmudar, C. Y., 
Pomerantz, W. C., Gagnon, J. K., Sadowsky, J. D., Meagher, J. L., Johnson, T. K., Stuckey, J. A., Brooks, C. L., 






in the context of ligand recognition, particularly with regard to small molecules. Furthermore, 
these results show that the ligand discovery strategy of Tethering
13–16
 can be expanded to 
targeting conformationally dynamic proteins and enable their structural characterization. 
 
Figure 3.1 The KIX domain is in the N-terminal region of CBP/p300. KIX interacts with >10 
amphipathic transcriptional activators using two distinct sites.
5-9
 MLL, HBZ and c-Jun target a 




B.1 The KIX domain 
The coactivators CBP and p300 are homologous and exist in a wide range of organisms from 
plants
17
 and C. elegans
18
 to rats and humans.
19
 The CBP/p300 proteins are transcription hubs that 
interact with numerous activators using multiple distinct well folded domains.
20
 The GACKIX 
domain, also known simply as the KIX domain, is one of these domains. This is a 90 residue 
domain that consists of a three helix bundle along with two 310 helices.
5
 The KIX domain is 
known to interact with more than ten distinct transcriptional activators
21
 via two different 
binding sites as shown in Figure 3.2. The complexes formed when KIX is bound to 
transcriptional activation domains (TADs) at one or both of its binding sites have been 
extensively studied by solution NMR:
1,5,22–24
 the helices α3 and α2 form a deep, narrow groove 
that interacts with transcriptional activators such as MLL, c-Jun and HBZ whereas on the 
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opposite side of the protein the helices α3 and α1 form a shallower, broader groove that binds to 
transcriptional activators such as pKID of CREB and c-Myb. There are also transcriptional 
activators that have been found to bind to either one of the two sites. For example, there are two 
TADs in FOXO3a, CR2C and CR3. Two different NMR structures of these tandem TADs 
binding to KIX exist: one with CR2C binding to the MLL site and CR3 binding to the pKID site 




Figure 3.2 Structure of the KIX domain of CBP in complex with two transcriptional activation 
domains, MLL and c-Myb at two distinct sites, α1, α2 and α3 label the three helices in KIX and L12 
depicts the loop region between α1 and α2. Based on PDB structure 2AGH 
 
Binding cooperativity is observed between the two sites when certain activators are 
involved.
5,6,8
 For example when either pKID or c-Myb is pre-bound to KIX, the binary complex 
shows a 2-fold increase in binding affinity to MLL. Similarly when either MLL or HBZ is pre-
bound to KIX, the binary complex shows a 2 and 6 fold increase in binding affinity to c-Myb, 
pKID will also bind to the KIX: MLL binary complex with a 2-fold increase affinity. Various 
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NMR and computational studies 
suggest that this cooperativity is 
due to an allosteric network 
interconnecting these two sites.
25,26
 
Ile 611, Ile 657 and Ile 660 serve 
as a bridge connecting Phe 612 at 
the MLL binding site with a series 
of residues on the pKID/c-Myb 
binding site, including Tyr 650, 
His 651, Ala 654 and Tyr 658 
(Figure 3.3). This domain has also 
been identified in other proteins, 
such as transcriptional coactivators 
Gal11 (Med15), Arc105
27
 and a 




There are several structures of the KIX domain in the Protein Data Base, and this information 
has proved invaluable in understanding the interaction between KIX and its activator binding 
partners as well as designing artificial ligands to target KIX. However, aside from the KIX-like-
domain of EBA-175 region VI, all the other structures are obtained by NMR in solution. We and 
others have attempted to crystallize the KIX domain (Dr. Malathy Krishnamurthy, data 
unpublished) under various screening conditions but with no success. Moreover, while both the 
NMR structures of Gal11(Med15)
29
 and Arc105 KIX
30
 domains are that of the free, unbound 
protein, all the structures of the KIX domain from CBP/p300 are solution structures of the 
 
Figure 3.3 The allosteric network: Phe 612 at the MLL 
site connects with Tyr 658, Ala 654, His 651 and Tyr 650 
at the pKID/c-Myb via Ile 611, Ile 660 and Ile 657. 




protein in complex with a peptide sequence of a transcriptional activator binding partner. Not 
only is there no structure of the free KIX domain of CBP, there is also no structure of the KIX 
domain in complex with a ligand solely at the MLL binding site. An atomic resolution structure 
of the KIX domain of CBP with no ligand at the pKID binding site would increase our 
understanding of this coactivator and its interactions with TADs. 
The lack of crystal structures and ligand-free structures of the CBP KIX domain might be 
attributed to the dynamic nature of this 
protein. Previous studies have shown both 
by protein solution NMR and molecular 
dynamics simulation methods that there are 
movements in KIX when transitioning 
between the binary (KIX:MLL or KIX:c-
Myb) and ternary (MLL:KIX:c-Myb) 
complex, as shown in Figure 3.4.
5,26
 
Notably, the L12 loop region and the C-term 
region of helix α3 undergo a significant 
conformational shift. It is suggested that 
this movement enables KIX to 
allosterically communicate between the two binding sites. 
As mentioned earlier, abnormalities in the interaction of KIX with its various TADs have been 
linked to a multitude of diseases. For example, atherosclerosis has been linked to transcriptional 
activators such as cAMP response element-binding protein (CREB) and c-Myb;
31,32
 the 
generation of hematopoietic stem cells is dependent on the transcriptional activator mixed 
 
Figure 3.4 Superposition of the KIX: c-Myb: MLL 
ternary complex (KIX: light blue, c-Myb: red, 
MLL: green) with the KIX: c-Myb binary complex 
(KIX: yellow, c-Myb: pink), showing the 









 cardiac hypertrophy has been linked to the master transcriptional 
coactivator CREB binding protein (CBP);
34
 and adult T-cell leukemia is linked to HTLV-1 basic 
leucine zipper factor (HBZ).
8  Thus, it is very important to develop small molecule modulators 
that target this interaction to act as therapeutics or mechanistic probes. However, there are very 
few small molecules that have been identified as KIX binders (see section B.2), and of the 
limited small molecules that have been found, low affinity and poor specificity remains a major 
road block for further developing them as useful modulators.
35–37
 Among the various obstacles in 
discovering small molecule modulators of protein-protein interactions, the lack of a high 
resolution and well-defined crystal structure of KIX stands out as an impediment in further 
progress on this front as well as for understanding the underlying mechanism of KIX-TAD 
interactions. 
 
B.2 Identified small molecule ligands of the CBP/p300 KIX domain and limitations 
A brief summary of the small molecules found to target the CBP/p300 KIX domain is listed 
below in Table 3.1. In short, despite the important role the KIX domain plays in various 
pathways across organisms, discoveries of small molecules that target this domain are few and 
far between. It is crucial to develop more small molecules that inhibit KIX in order to probe the 
mechanism of action of this allosterically regulated transcriptional coactivator to both further 
develop therapeutic strategies and to elucidate the general mechanism of transcriptional protein-
protein interactions from this prototypical system. New screening approaches must be used to 
find small molecule binding partners of KIX. Also appropriate small molecule ligands would 
possibly serve as a stabilizer for KIX conformation, hence enable the crystallization of KIX and 
provide us with more details of the mechanism. 
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Table 3.1 Summary of small molecules known to target the KIX domain of CBP/p300 
Compound Method of Discovery Target Site 








NMR based screen 
pKID/c-Myb 
site 
(Ki ≈ 90 μM, 
KD =115 μM) 
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(IC50 = 2.9 μM, 
KD =8.6 μM ) 
 



















(KD = 38 μM) 












(IC50 = 17 μM) 
MLL/c-Jun site 
(IC50 = 34 μM) 
Majmudar, C. Y., 









(IC50 = 25 μM) 
MLL/c-Jun site 
(IC50 = 17 μM) 
Majmudar, C. Y., 






B.3 Tethering and other small molecule ligands stabilizing proteins 
In recent years, the concept of using small molecules to target large protein surfaces at 
protein-protein interaction (PPI) interfaces, including transcriptional complexes, has become 
increasingly visited,
41–43
 despite the many difficulties such as lack of defined deep binding 
pockets and in many cases even lack of defined structure and conformation.
2,44
 While the search 
for a small molecule inhibitor is the more common approach in these cases,
36,45–50
 there are also 
studies emerging where small molecules are demonstrated to stabilize the protein-protein 
interaction
51
 or even trapping an otherwise conformationally dynamic protein in a single more 
desirable conformation. Some recent examples of the latter include small molecules locally 
stabilizing two 10-20 residue long sequences of c-Myc forcing it into a conformation unable to 
form heterodimers with binding partner Max;
52
 an allosteric inhibitor of the hepatitis C virus 
NS3 protein that locks the helicase/protease protein into a “closed” conformation hence 
inhibiting its proteolytic activity;
53
 and small molecules with a Michael acceptor moiety that 




Identifying small molecule ligands targeting PPI surfaces pose many challenges including 
large binding surface and lack of structure; initial hits often bind to the target protein with 
comparatively low affinity, and are easy to be presented as false negative results in a screen. One 
way to avoid missing these low affinity ligands would be to use the Tethering technique 
designed by James Wells’ laboratory.
16
 This strategy utilizes a small library of disulfide-
containing fragments that are able to form covalent bonds with native or engineered cysteines in 
the target protein. The covalently bound small molecules are then amenable to detection by 
techniques such as mass spectrometry. Varying the concentration of competing disulfide-forming 
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molecule such as beta-mercaptoethanol controls the stringency of the screen. Once these weak-
binding fragments are identified as leads one can improve upon the binding affinity by 
synthesizing a small set of analogs.
16
 Also these can be converted into irreversible small 
molecule binders without extensive modifications (Mapp lab, data unpublished). Additionally, 
from a more interesting perspective, this technique can also serve as a probe for studying protein 
mechanisms of action. The Wells lab has been able to uncover a new common allosteric site on 
caspases using Tethering to trap disulfide inhibitory small molecules,
14,15
 and have also used this 
method to characterize an allosteric site on protein kinase PDK1 as well as demonstrate that 





C. Experimental Design 
 
Figure 3.5 Schematic of the Tethering screen used to identify small molecule fragments (1-10 and 
2-64) that form a disulfide bond with a cysteine introduced at position 664 (L664C) within KIX.  
 
We screened for small molecules that interact with the KIX domain using the Tethering 
approach,
16 
a strategy that provides a mechanism for the rapid discovery of covalent ligands 
(Figure 3.5). Attention was focused on the binding site that is targeted by the transcriptional 
77 
 
activation domains of proteins such as the Mixed Lineage Leukemia (MLL) activator and c-Jun; 
the Tethering approach is a fragment discovery method and the smaller, deeper MLL/c-Jun 
binding site appeared the more targetable by low molecular weight compounds.
35,38
 Towards this 
end, a residue at the rim of the binding surface, L664, was mutated to a cysteine and the resulting 
KIX L664C mutant fully characterized. Small molecule fragments containing a disulfide motif 
were then screened for the ability to form a disulfide bond with KIX L664C in the presence of a 
competitor, β-mercaptoethanol. Two fragment ligands emerged from the screen with high 
Tethering efficiency to KIX L664C as quantified by DR (Dose Response) 50 values (2-8 μM), 
fragments 1-10 and 2-64 (Figure 3.5).  
 
D. Results 
D. 1. Binding affinity of small molecule-tethered KIX L664C to TAD peptides. 
To assess the effect of tethered 1-10 or 2-64 on the binding properties of KIX, fluorescent 
anisotropy binding assays were used to measure the binding affinity of wild type KIX, KIX 
L664C and fragment-tethered KIX L664C complexes to native transcriptional activator ligands 
that target the two different binding sites (Table 3.1 and Figure 3.6). Consistent with the screen 
design, the presence of 1-10 or 2-64 decreased MLL binding to KIX L664C by ~22 to 33-fold 
(Table 3.2). Also, while tethered 2-64 does not affect KIX’s binding affinity for pKID, the 
transcriptional activation domain of CREB that interacts with the distal binding site,
23
 KIX 
tethered to fragment 1-10 does exhibit attenuated binding to pKID (~2-fold). This suggests that 







Figure 3.6 Direct binding affinity of fluorescently labeled peptides a) MLL19-FITC or b) pKID29-
FITC to varying concentrations of KIX wt (black triangles), KIX L664C (black circles),  1-10—KIX 
L664C (teal squares) and 2-64—KIX L664C (blue triangles) was determined by fluorescence 
anisotropy. Each data point was taken in triplicate, error bars depict standard deviation (SD). See 
methods for more information. 
 
Table 3.2 KDs for KIX constructs interacting with fluorescein-labeled MLL and pKID peptides were 
determined by fluorescent anisotropy. Each KD is a fitted result of experiments performed  in 
triplicate with the indicated error (SD). 
 
 
D.2. Thermal, proteolytic and solvent stability of small molecule-tethered KIX L664C 
The tethered fragments significantly altered the stability of the KIX domain. This was 
assessed for each of the fragment-protein pairs by measuring changes in CD-monitored thermal 
melting temperature, amide hydrogen-deuterium (H-D) exchange and thermolysin-mediated 




Figure 3.7 Bar graph depicts the percent increase in melting temperature (TM) upon tethering to either 1-
10 or 2-64 as monitored by circular dichroism (blue bars) and the percent of backbone amides protected 
from H-D exchange upon attachment of the small molecules (red bars). The green bars represent the fold-
increase in resistance to thermolysin degradation of the KIX mutants when tethered to 1-10 and 2-64. 
Data is normalized to KIX L664C.  
 
To assess the effect of tethered small molecules to the global protein stability of KIX, we 
obtained the melting temperature of 1-10—KIX L664C and 2-64—KIX L664C by fitting the 
decrease of helical content (reflected by circular dichroism) over a temperature scan.  As shown 
in Figure 3.8, the thermal stability was greatly increased in both complexes: the 1-10—KIX 
L664C and the 2-64—KIX L664C complexes exhibit a 15-18 °C (≥20%) increase in melting 
temperature.  
 
Figure 3.8 Melting temperature curve obtained by plotting molar ellipticity (obtained from circular 
dichroism measurements) at 222 nm during heating of the protein solutions at a rate of 1 
degree/minute from 20-95°C. 
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To probe for the protection of backbone amide protons by small molecules 1-10 and 2-64, we 
carried out hydrogen-deuterium (HD) exchange experiments with tethered and free KIX 
L664C.
13
 The mass of free KIX L664C shifted 29 Da upon exposure to D2O for 1 min as 
monitored by mass spectrometry,
13
 whereas the mass shift was 17 and 13 Da when 1-10 and 2-64 
were tethered to KIX L664C,  respectively, showing that 40%-55% of the exchangeable amides 
were protected from H-D exchange compared to the free protein.  (Table 3.3)  
 
Table 3.3 Difference in number of amide protons protected from solvent. 
 
 
To probe the energetic stability of KIX when tethered to small molecules, we carried out 
pulse proteolysis with a nonspecific protease thermolysin.
13,55
 The protease reaction was 
quenched at several time points and run on SDS-PAGE. The amount of protein remaining in 
each lane was quantified on the gel using ImageJ. The proteolytic stability (half-life) of the 
tethered complex increased 5-37 fold compared to the untethered protein, (for 1-10 for example: 
T½ of 10 minutes versus 2.1 minutes) as shown in Figure 3.9.
55,
 This demonstrated that 1-10 and 
2-64 stabilize KIX from degradation when covalently tethered to the protein. These findings 




Figure 3.9 Proteolytic stability assays for free KIX L664C and KIX L664C covalently tethered to a) 1-10 
or b) 2-64. Half-life of the protein-small molecule complex was compared to free KIX L664C half-life in 
the same experiment using the same batch of thermolysin, avoiding systemic errors such as inconsistent 
enzyme activity. See methods for more information. 
 
 D.3.Crystal structure of 1-10—KIX L664C 
Of the various fragment—protein complexes and conditions that were screened (see Table 
3.4), the best results were obtained with 1-10—KIX L664C under the crystallizing condition of 
1.8 M ammonium sulfate and 0.1 M Tris, pH 7.0 at 25° C, leading to crystals amenable for 
diffraction. However, only microcrystals of 2-64 tethered to KIX L664C were obtained and were 
of too poor quality to solve.  Initially, molecular replacement strategies using the NMR structures 
of KIX bound to native transcriptional activation domains were used but did not lead to the 1-
10—KIX structure.
5,23
 Therefore, a selenomethionine-incorporated KIX L664C tethered to 1-10 
were prepared and the X-ray structure was solved. Using these data, the structure of 1-10—KIX 
L664C was determined to 2.0 Å resolution.  




















As illustrated in Figure 3.10a, the small molecule 1-10 sits within the MLL/c-Jun binding site 
of KIX, and is oriented  toward the core of the protein between helices α3(residues 646-664) and 
α2(residues 623-638). Notably, the aromatic ring of 1-10 is positioned relatively deep in a 
hydrophobic pocket lined by the side chains of Ile611, Leu628, Leu607, Val635, and Tyr631 
(Figure 3.10c); Leu628 and Tyr631 have previously been shown to be key residues involved in 
KIX interacting with MLL.
5,56
 Tyr631 in particular, closely contacts the aromatic ring of 1-10 
(~4Å), illustrated by the above 2σ deviation of the Tyr631 φ and ψ angles. This is consistent with 
data from a solution binding study of untethered 1-10 interacting with KIX containing 
19
F-




 Consistent with 
these data, chemical shift perturbation experiments with 
15
N-labeled KIX L664C free and 
covalently tethered to 1-10 (Figure 3.10a) revealed significant changes in the backbone amide 
shifts of the residues lining the hydrophobic binding surface for 1-10 (Ile611, Leu628, Leu607, 
Val635 and Tyr631). 
 
Figure 3.10 a) Refined crystal structure of KIX L664C covalently tethered to fragment 1-10. Refined 
resolution = 2.0 Å, Rwork/Rfree= 0.2064/0.2329. b) Crystal structure of KIX L664C tethered to 1-10 (teal) 
superimposed using Coot on the NMR solution structures of KIX in complex with cognate transcriptional 
activation domains: pKID (yellow, PDB ID 1KDX, R.M.S.D. =1.40 Å); with MLL and c-Myb (deep blue, 
PDB ID 2AGH, R.M.S.D. =1.80 Å); with PCET (purple, PDB ID 2KWF, R.M.S.D. =1.81 Å); and with 
FOXO3A (black, PDB ID 2LQH, R.M.S.D. =1.07 Å). c) Interactions between 1-10 (yellow) and residue 
side chains of KIX L664C (blue) at the binding surface. d) 3σ electron density map (Fo-Fc) of 1-10 




The prevailing structural model of the amphipathic class of activator-coactivator complexes 
is that the activator forms an amphipathic helix upon binding to the surface of the 
coactivator.
1,57,58
 Although only a limited suite of surfaces have been characterized, the available 
data suggest that the binding surfaces are often broad,
2,59
 making them particularly challenging to 
target with small molecules that have far less volume and surface area than the typical helix of a 
transcriptional activator.
60
 Overlay of the 1-10—KIX L664C structure with the averages of the 
previously reported NMR structures of KIX-ligand complexes
5,22,24
 yields R.M.S.D. values 
between 1.07-1.81 Å, demonstrating the overall similarities in the backbone structure. The 
exception to this similarity is in the loop region (residues 612-622) between helices α1 and α2, 
which deviates significantly with R.M.S.D. values between 2.73-3.11 Å (Figure 3.10b). This 
difference is not surprising, as conformational changes in the loop regions are thought to be 
integral to the ability of KIX to accommodate diverse native ligands.
5,22,23,26






N-HSQC analysis of small molecule-tethered KIX conformational change when 
binding to ligands at the MLL site 
Chemical shift perturbation experiments with 
15
N-labeled KIX L664C free and covalently 
tethered to 1-10 (Figure 3.11 and Figure 3.12) revealed significant changes in the backbone 
amide shifts of the residues lining the hydrophobic binding surface for 1-10 (Ile611, Leu628, 
Leu607, Val635 and Tyr631). In addition, the significant perturbations of residues Ile611 and 
Ile660 upon 1-10 tethering are consistent with the attenuated affinity of pKID for the distal 
binding site, as these residues are a critical part of the allosteric network that comprises the 
communication between the two binding sites within KIX. Upon comparison to chemical shift 
perturbation experimetns performed on KIX L664C free and incubated with 2 molar equivalents 
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of MLL peptide, there are many similar regions of large chemical shift perturbations between 
that elicited by MLL and 1-10 (Figure 3.12 and Figure 3.13).  An identical chemical shift 
perturbation experiment with 2-64 tethering to 
15
N-labeled KIX L664C showed similar trends 









N KIX L664C (red) overlaid with 
15
N 1-10—KIX L664C (blue) and 
15
N 2-64—KIX L664C (green) and 2xMLL incubated with 
15
N KIX L664C (yellow) . Small 








N-HSQC) with 1-10-tethered 
KIX L664C. Residues that shifted more than 1 SD upon 1-10 tethering are in yellow and include Ile611, 
Leu628, Leu607, Val635 and Tyr631, and Ile660; b) Chemical shift perturbation mapping of KIX L664C 
residues upon tethering to 1-10. Residues that shift >1 SD are assumed to be significant (dotted line), see 








N-HSQC) with 2x MLL 
pre-incubated with KIX L664C (using structure of 1-10—KIX L664C for comparison). Residues that 
shifted more than 1 SD upon addition of MLL are in yellow; b) Chemical shift perturbation mapping of 
KIX L664C residues upon pre-incubating with 2 molar equivalents of MLL. Residues that shift >1 SD are 
assumed to be significant (dotted line), see methods for details. Residues that are unable to be 




Figure 3.14 a) Results from chemical shift perturbation experiment (1H- 15N-HSQC) with 2-64-tethered 
KIX L664C. Structure of 2-64----KIX L664C is a simulated structure closest to the calculated average of 
the 40 ns molecular dynamics simulation started from the top docking result. Residues that shifted more 
than 1 SD upon 2-64 tethering are in yellow; b) Chemical shift perturbation mapping of KIX L664C 
residues upon tethering to 2-64. Residues that shift >1 SD are assumed to be significant (dotted line), see 
methods for details. Residues that are unable to be detected/assigned are shown in gray. 
88 
 
E. Discussion and Conclusions 
To dissect in more detail how the KIX surface remodels itself to recognize fragment 1-10 
Jessica Gagnon from the Brookes lab carried out 40 ns molecular dynamics simulations of the 
KIX crystal structure with or without ligand 1-10. A gross comparison of the backbone reveals 
that a change in the loop conformation is the most significant. These changes are often difficult 
to visualize by solution methods because the loop region contains several proline residues, but 
mutagenesis and NMR methods have suggested that conformational plasticity in this region 
underlies the ability of KIX to recognize diverse amphipathic sequences.
5,25,26
 It is this 
movement of the loop and a rotation of helix α1 that enable the formation of a narrower binding 
surface to accommodate a molecule that is considerably smaller than a peptidic helix (~77% 
smaller volume). 
The binding surface that is targeted by 1-10 is also significantly different, both as a result of 
loop conformational changes and because of side chain motions as demonstrated by the change 
in solvent accessible surface area of the residues when the fragment is tethered (Figure 3.15a). 
For example, the liganded KIX shows a population shift in the Tyr 631 side chain χ angles 
relative to the simulated untethered protein, leading to a hydrophobic binding surface for deeper 
interactions (Figure 3.15b). Simulations of 2-64 tethered to KIX L664C suggest that the binding 
mode of this ligand is similar to that of 1-10 and further demonstrates the ability of this protein to 




Figure 3.15 a) The difference in the average SASA (Solvent Accessible Surface Area) calculated by 
residue between simulations of KIX L664C untethered and tethered to 1-10 in units of Å
2
. A residue 
colored red is less solvent-exposed in the 1-10-tethered structure, with color intensity indicating the extent 
of the change; blue resides are more solvent-exposed in the 1-10-tethered structure.  b) Comparison of the 
orientation of Tyr631 populations in the 1-10-tethered KIX L664C (blue) and the simulated free KIX 
L664C (green). c) Fragment 2-64 tethered to KIX L664C structure closest to the calculated average of the 
40 ns molecular dynamics simulation started from the top docking result, with the fragment in blue and 
protein in gray. Simulations performed by Jessica Gagnon. 
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While there are several crystal structures of proteins with small molecules covalently tethered, 
the proteins involved all had crystal structures without tethering to a small molecule as well. This 
is the first time a small molecule has been shown to stabilize a formerly uncrystallizable protein 
to form diffraction-quality homogenous crystals. This suggests a great potential for using small 
molecule tethering as a tool to stabilize and enable conformationally dynamic proteins to form 
crystals in addition to established methods such as pre-incubating protein with small molecule 
inhibitors and “stapling” certain residues on a protein. 
While this structure of 1-10--KIX L664C does not fully reflect the conformation of the free 
KIX domain, it is highly possible that this conformation is one of many conformations that the 
KIX domain samples in solution, trapped and “frozen” by a small molecule stabilizer. This 
presents the potential of further crystallizing small molecule-tethered-KIX in complex with 
different small molecules and TAD peptides. As crystal structures enable us to examine the exact 
side chain orientations at atomic levels, comparing these structures will enable us to identify 
specific side chain changes and helix twist changes upon different ligands binding to KIX.  
In conclusion, we have obtained a 2Å-resolution snapshot of the conformationally dynamic 
coactivator KIX domain complexed with a small molecule. This will significantly facilitate using 
rational structure-based approaches to design more potent analogs; for example, current efforts 
include extending the molecule 1-10 at the C4 position of the aromatic ring in order to more 
effectively engage with the hydrophobic space within the KIX site. From a broader perspective, 
these results in combination with recent studies showing noncovalent small molecules stabilizing 
conformationally dynamic proteins
53,61
 suggest that Tethering may be an exceptionally enabling 
approach to obtain long-sought x-ray crystallography data of conformationally dynamic proteins. 
This includes transcriptional coactivators such as CBP/p300 targeted here, but also members of 
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F. Future Directions 
Efforts to move this project further include plans to modify the reversible disulfide moiety of 
the tethered fragment hits into a series of irreversible alkylating moiety-containing molecules. 
These modifications will be examined for their ability to modulate MLL and pKID or c-Myb 
binding to KIX. There will also be modifications on the fragments such as a biotin handle to 
enable in-cell pull down studies based on the streptavidin-biotin interaction. Through this we will 
be able to globally analyze the proteins that the small molecules target within cellular 
environments and asses the specificity of these small molecules. There has also been simulation 
work done by Jessica Gagnon and Sarah Graham from the Brookes lab evaluating the theoretical 
binding affinities of 1-10 fragments with several side chains modified. They have identified a 
few key modifications that prove to be promising as a KIX binder in silico. Future plans include 
synthesizing these small molecules and testing them against various KIX mutations. Both of 
these endeavors will be carried out by a graduate student Jean Lodge and a postdoctoral fellow 
Dr. James Clayton in the lab. 
Additional KIX cysteine mutants have also been cloned and expressed where the cysteine is 
positioned at the pKID/c-Myb binding site of KIX. These KIX constructs will undergo a 
modified Tethering screen where initial screening will be through an FP based assay (designed 
by former postdoctoral fellow Dr. William Pomerantz in the lab) and then the initial hits 
confirmed by mass spectrometry as the previous study. The screens will be carried out by the 
Wells lab at UCSF in collaboration with Jean Lodge in the Mapp lab. 
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  Crystallization efforts will be continued with additional fragment hits and modified 
fragments identified and evaluated in the aforementioned projects. We will also focus on 
crystallizing tethered KIX mutants in complex with transcriptional activator peptides that bind to 
the other unoccupied site of KIX, in hope of elucidating the allosteric effect of small molecule 
tethering to the conformation of both the activator peptide and KIX itself. 
  
H. Experimental Methods 
Protein Expression and Purification 
  As previously described,
38
 the DNA sequence encoding the KIX domain of mouse CBP 
(586-672) was cloned into a pRSETB vector incorporating a hexahistidine tag with a short linker 
fused to the N-terminus of KIX for protein expression resulting in a protein with sequence (tag 
and linker residues are shown in lower case):  
mrgshhhhhhgmasGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKDRRMENLV
AYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRL  
The cysteine mutant at KIX L664C was created using site-directed mutagenesis as previously 
described.
38
  For protein expression, the plasmid was transformed into Rosetta2 (DE3) pLysS E. 
coli (Novagen) and grown in LB media. After an O.D.600 of 0.8 was reached (37 °C, 250 rpm), 
the cultures were cooled to 25 °C and expression was induced with 0.5 mM IPTG for 4 h (250 
rpm). The His-tagged protein was isolated using Ni-NTA beads (Qiagen) according to the 
manufacturer’s instruction and eluted with 400 mM imidazole.  Final purification was carried out 
by ion-exchange column chromatography on a Source S column, (GE Healthcare) in 50 mM 
phosphate buffer, 1 mM DTT, pH 7.2 eluting with increasing concentrations of NaCl (0-1 M 
NaCl).  Purified protein solutions were buffer exchanged into 10 mM sodium phosphate, 100 
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mM NaCl, 10 % glycerol 0.01 % NP40, pH 6.8 using a PD-10 column (GE-Healthcare) and 
stored at -80 °C.   
  Selenomethionine incorporated KIX L664C was expressed as previously described using 
Rosetta2 (DE3) pLysS E. coli .
64
 KIX L664C was expressed in minimal media M9 supplemented 
by amino acid mixture containing Selenomethionine as previously described
64
 and purified as 
described above. Selenomethionine incorporation was confirmed by Q-TOF LC-MS (Agilent). 
 
Peptide Synthesis and Purification 





Fragment Screening and DR50 Determination 
  To identify molecules that interacted with KIX a 480-member disulfide fragment library 
(SMDC, UCSF) was screened in a high-throughput format using a mass spectrometry based 
assay.
16
 Immediately prior to screening, the bacterially expressed KIX L664C was buffer 
exchanged to 10 mM sodium phosphate pH 6.8, 100 mM NaCl, 5 mM β-ME using a PD-10 
column (GE Healthcare). Next, 2 μM of the buffer exchanged KIX cysteine mutant was 
incubated with 500 μM of each fragment with shaking for 1 h at room temperature (25 μL total 
volume in a 96-well plate). Subsequently, the plate was moved to 4 °C and the mass of each well 
measured using a LCT-Premier LC/electrospray ionization-MS instrument (Waters). Protein 
masses were deconvoluted using the Max-Ent algorithm within the MassLynx software. 




  Dose Response (DR)50 values were determined as previously described.
13
 Varying 
concentrations (500-0.2 μM) of the fragment molecules were incubated with 2 μM KIX mutant 
protein (at 1mM β-ME) for 1 hour at RT. The percent of protein tethered to fragment molecules 
were determined by Q-TOF LC-MS (Agilent). The concentration of fragment molecule required 
for 50% maximum tethering (DR50) was determined by data analysis in GraphPad Prism 
software, fitting to Equation 3.1, where x is the log of fragment molecule concentration and y is 
the normalized response from 1 to 100 (percent of protein tethered to fragment molecule). 
   (Eq 3.1) 
 
Fragment Tethering  
  KIX L664C was incubated with 10 equivalents of 1-10 or 2-64 in 50 mM phosphate buffer 
at pH 6.8 overnight, excess small molecule was removed by NAP-5 desalting column and buffer 
exchanged into 20 mM HEPES, 100 mM NaCl, pH 8.0. Small molecule tethering efficiency was 
confirmed by Q-TOF LC-MS (Agilent) and tethering reached at least 95% complete. Protein-
small molecule complexes were flash frozen in liquid N2 and stored at -80°C. 
 
Circular Dichroism 
  CD spectra were acquired on a J-715 spectropolarimeter equipped with a temperature 
control unit (Jasco, Inc., Easton, MD). Briefly, samples of 10 μM KIX L664C were treated with 
DMSO or small molecule fragments (10 eq.) and tethered >95% (overnight, room temperature 
and confirmed by quantitative LC-MS) in 10 mM sodium phosphate pH 6.8, 100 mM NaCl, < 2% 
DMSO, 0.1 mM β-ME. CD spectra were recorded using a 1 mm path length quartz cuvette. The 
CD signal resulting from the buffer alone was subtracted from the spectrum of each protein 
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solution. Variable temperature CD was acquired by monitoring the molar ellipticity at 222 nm 
during heating of the protein solutions at a rate of 1 degree/minute from 20-95 
°
C.  Data were 




) according to the Equation 3.2: 
[Θ] = Ψ / (1000*n*l*c)     (Eq. 3.2) 
 Where Ψ is the CD signal in degrees, n is the number of amides, l is the path length in 
centimeters, and c is the concentration in decimoles per cm
3
. Data analysis was performed 
using GraphPad Prism software to calculate the melting temperature. 
 
Hydrogen-Deuterium Exchange 
Hydrogen-deuterium (HD) exchange experiments were carried out with tethered and free 
KIX L664C to probe for the protection of backbone amide protons by small molecules 1-10 and 
2-64 following procedures similar to previous work by Wells et al. 
13
 Frozen aliquots (100 μM) 
of KIX L664C, 1-10—KIX L664C and 2-64—KIX L664C were thawed on ice, these solutions 
were then diluted 4-fold into 12.5 mM Tris 50 mM NaCl  in 97.5 % D2O and 2.5 % H2O, pH 7.0 
directly in a mass spectrometry sample vial. The vial was immediately placed in the automatic 
sampling plate (4°C) of the Q-TOF HPLC-MS (Agilent). The sample was injected onto the mass 
spectrometer 1 minute after exposure to D2O. Subsequently for comparison, another vial with the 
protein/ protein-small molecule complexes diluted 4-fold into 12.5 mM Tris 50 mM NaCl in 100 % 
H2O, pH 7.0 was injected on the mass spectrometer as well. Data was analyzed by Agilent 
Qualitative Analysis Program. The difference in molecular weight with and without deuterium 
exchange was calculated, and percent amides protected was calculated as 100 %- (Δ (1-10 or 2-





25 μL of KIX L664C, 1-10—KIX L664C and 2-64—KIX L664C were diluted in 225 μL of 
proteolysis buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.5 mM CaCl2, 4.5 M Urea) to yield 
a final protein concentration of 15 μM and incubated at RT for 1 hr. Thermolysin from a 10 
mg/mL stock solution was added to the protein at a 1:30 molar ratio. 15 μL of the proteolysis 
reaction was added to 5 μL of 50 mM EDTA to quench proteolysis at various time points and 
stored at -20 °C. The quenched samples were analyzed by SDS-PAGE (12 % Bis-Tris gel in 
MES running buffer, staining with comassie blue). Band intensities were analyzed by ImageJ 
imaging software. Percent protein remaining was plotted against time and fit to an exponential 




Fluorescent Anisotropy Assays 
  The fluorescent anisotropy assays were done in triplicate with a final sample volume of 10 
μL in a low volume, non-binding, black, 384-well plate (Corning), and read using a Tecan 
Genios Pro plate reader with polarized excitation at 485 nm and emission intensity measured 
through 
a parallel and perpendicularly polarized 535 nm filter. FITC (Fluorescein isothiocyanate) 
labeled peptides were diluted in storage buffer (10 mM Phosphate, 100 mM NaCl, 0.01 % NP-
40, 10 % Glycerol, pH 6.8) to a concentration of 25 nM. Then 10 µL of the peptide solution was 
added to a series of 50 µL solutions of varying KIX concentrations in storage buffer to obtain the 
final concentrations of up to 20 μM. The samples were incubated for 30 min at room temperature 
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before the degree of fluorescence anisotropy was measured (Tecan Genios Pro). A binding 
isotherm that accounts for ligand depletion (assuming a 1:1 binding model of peptide to KIX) 
was fit to the observed anisotropy values as a function of KIX to obtain the apparent equilibrium 
dissociation constant, KD: 
    (Eq 3.3) 
where “a” and “x” are the total concentrations of fluorescent peptide and KIX, respectively, 
“y” is the observed anisotropy at any KIX concentration, “b” is the maximum observed 
anisotropy value, and “c” is the minimum observed anisotropy value. Each data point is an 
average of three independent experiments with the indicated error (standard deviation). Data 




  Initial conditions found for crystallization of 1-10—KIX L664C was from Index-HT
TM
 
condition A5 (2.0 M Ammonium sulfate, 0.1 M HEPES pH 7.5). 
   Purified Selenomethionine incorporated 1-10—KIX L664C was concentrated to 4.5 
mg/mL in 25 mM HEPES, 100 mM NaCl buffer (pH 6.5) prior to crystallization. Crystals were 
grown by hanging drop vapor diffusion at 20 °C with drops containing 2 μL protein and 2 μL 
precipitant (1.8 M (NH4)2SO4, 0.1 M Tris-HCl pH 7.0). Crystals were soaked in well solution 
containing 10 % ethylene glycol, then transferred to a solution of 20 % ethylene glycol for 




Data Collection and Refinement 
  Data were collected at the Advanced Photon Source (LS-CAT Beamline 21-ID-F) at the 
Argonne National Laboratory equipped with a Mar225 detector at wavelength of 0.97852 Å and 
−180 °C. Data were processed and scaled with HKL2000.
65
 1-10—KIX L664C crystallized in 
space group P43212, with unit cell parameters of a = b = 48.330 Å, c = 85.464 Å, and α = β = γ = 
90°. Phases were initially determined by single wavelength anomalous X-ray scattering of the 
selenenium atoms using AutoSol in Phenix.
66
 The program identified three Se atom sites, 
pertaining to the two ordered Se-methionines in the KIX structure. One Se-Met residue had two 
equivalent positions; the other two Se-met residues were located in the disordered N-terminal 
region. The resulting structure was fit in Coot
67
 using the 2Fo − Fc and Fo − Fc electron density 
maps from Phenix, followed by rigid body and restrained refinement in Buster.
68
 After 
refinement clear Fo − Fc electron density was apparent for compound 1-10. Three-dimensional 
coordinates and buster style restraint files for the compound were generated in GRADE
69
 using a 
smile string created by the PRODRG web server.
70
 Iterative rounds of fitting in Coot and 
refinement in Buster of the 1-10—KIX L664C structure to 2.0 Å resulted in Rwork = 20.6% and 
Rfree = 23.3%.  
  All residues from the three structures are in the allowed regions of the Ramanchandran plot. 






 Ligand statistics were 
obtained from the Uppsala Electron-Density Server.
74
 Areas of poor electron density were not 
modeled. These areas include side chains of residues Arg 588, Lys 621, Asp 622, Asp 638, Lys 
662 and Glu 665.  The N-terminal His tag along with N-terminal residues 584-587 and C-
terminal residues 666-672 were disordered in the structure. Data refinement and statistics are 






N-HSQC NMR Experiments 
  Uniformly 
15
N labeled KIX L664C protein was expressed and purified as previously 
described.
40
Samples of the purified 
15
N labeled KIX L664C were tethered with small molecules 
1-10 or 2-64 as described above. A 45 μM solution of 
15
N- labeled KIX L664C with or without 
small molecule was prepared in a 9:1 H2O:D2O 10 mM sodium phosphate buffer containing 100 




N HSQC experiments were recorded at 27 
o
C on an Avance Bruker 
600 MHz NMR spectrometer equipped with a 5 mm cryogenic probe.  HSQCs were collected 
with the protein itself, the protein covalently tethered to 1-10 or 2-64 and the chemical shifts 
were compared. Data was processed using NMRpipe
75
 and analyzed in Sparky (UCSF).
76
       
Chemical shifts of residues were identified based on previous assignments.
35
 Chemical shift 










, which is a weighted 
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Chapter 4 Kinetic Characterization of a Transcriptional 
Coactivator (KIX) in Complex with Peptide and Small 
Molecule Binding Partners 
 
A. Introduction 
Chapter 2 outlined our study on the kinetic mechanism of TAD-Med15 interactions. 
However there is little structural information on either the TADs involved or the coactivator 
Med15. This deters further study on the conformational change aspect of the interaction, which 
we have found to play a key role in TAD potency.
1
 Hence a model system with more detailed 
structural information is needed. One such system is the TAD-KIX complex. The interaction 
between disordered transcriptional activators and the conformationally dynamic KIX domain of 
the coactivator CBP has long served as a prototypical case study for the kinetics and 
conformational dynamics of protein-protein interactions involving highly flexible components.
2–6
 
The conformational changes that the TADs and KIX undergo upon binding along with the 
allosteric interaction between different TADs at distal binding sites of KIX have been examined 
by various NMR studies.
2,7,8
 However, aspects of these interactions remain poorly understood. 
For example, the underlying mechanism of the allostery between the two binding sites on the 
KIX domain has yet to be well defined, as well as the ability of different protein ligands to elicit 
different degrees of allosteric effects.
9,10
 In addition, there is limited study on small molecule 
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modulators that target this interaction.
11,12
 To address this problem, Mapp and coworkers have 
recently performed a disulfide screen using Tethering
13
 technology to identify several small 
molecule fragments that can selectively tether to cysteine mutations introduced within the KIX 
domain.
14,15
 Two molecule fragments that stand out as having high binding affinity to KIX 
mutants are 1-10 and 2-64. Interestingly, these tethered small molecules are able to allosterically 
affect pKID binding at the distal site of KIX to varying extents. In this chapter the underlying 
transient-state kinetics mechanism of this small-molecule elicited allosteric regulation is studied 
in detail using stopped-flow spectroscopy. While pKID association constants are similar across 
different protein-protein and protein-small molecule complexes, we find that the dissociation 
constant best reflect the change in KIX’s affinity to pKID. We further noticed that 1-10 can elicit 
distinct allosteric effects on the pKID binding of KIX depending on the site at which it is 
tethered. Thus, 1-10 is a potentially powerful probe to dissect the allosteric mechanism that 
governs this prototypical coactivator motif. 
 
B. Background 
B.1. The KIX domain interacts with the TADs of MLL, c-Myb and pKID 
  Three well-studied TADs that bind to KIX with low micromolar affinity are those of MLL, 
pKID (phosphorylated kinase inducible domain of CREB), and c-Myb. The binding site targeted 
by MLL is located on the opposite binding surface as that targeted by both pKID and c-Myb, 
albeit in different orientations (Figure 4.1).
7,8
 As mentioned in Chapter 3, c-Myb and pKID can 
each bind cooperatively to KIX with MLL,
7,16
 NMR studies have suggested that this is enabled 
by an allosteric network between the two binding sites.
17
 All three of these TADs are considered 
to be intrinsically disordered proteins (IDPs). While there are detailed studies on each of the 
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three activators binding to KIX separately, 
research in the field has mainly focused on 
elucidating the mechanisms of the c-Myb 
and pKID binding interactions.
2,3,18–23
 As is 
the case with many studies on TAD-
coactivator interactions, all the TADs used 
in the following studies as well as structure 
determination were isolated peptide 
fragments. 
KID is the kinase inducible domain of 
the cAMP response element binding protein 
(CREB), and when isolated in vitro, this domain is unstructured.
21
 However, upon 
phosphorylation of Ser133 by protein kinase A, the domain (now named pKID) binds to the KIX 
domain and assumes a helical structure.
8,21
 Computational and experimental data suggest the 
phosphorylated serine contributes to pKID’s affinity to KIX by both electrostatic interactions as 
well as hydrogen bonding with Lys 662 or Tyr 658 on KIX.
8,24
 Interestingly, phosphorylation of 
a different serine residue on KID, Ser142, attenuates its ability to bind KIX, thus suggesting this 




NMR relaxation studies and simulations using a Go-type model have suggested a three-step 
mechanism for the pKID-KIX interaction (Figure 4.2).
2,25
 in which pKID is initially 
unstructured when it encounters KIX,
26
 and only assumes the helical structure in the final bound 
complex. Furthermore, the overall on-rate (kon) for this binding process from the “encounter” 
 
Figure 4.1 Overlay of structures 1KDX and 
2AGH, showing both c-Myb (green) and pKID 
(blue) binding to the KIX domain (grey). MLL 




complex to the “bound” complex has been determined to be an average of 6.3 μM-1s-1 by NMR 
relaxation studies.  
 
Figure 4.2 Schematic of the coupled folding and binding mechanism proposed for the pKID-KIX 
interaction. Orange sphere refers to the phosphorylated Ser133 on pKID.  
In particular, it must be noted that the first step from “free” to “encounter” was proposed as a 
theory, but the time scale on which this step would occur is too fast to observe by the techniques 
employed. This step was supported, however by computational simulations.
25
 The same 
computational study also observed that increasing the helical propensity of pKID actually led to 
a decrease in its association rate with KIX. This finding is consistent with the “fly casting” 
model,
27
 where a more flexible, less structured protein has larger available surface area to 
encounter a binding partner, resulting in a faster association rate. 
Studies have shown that although c-Myb and pKID bind to KIX at the same site, the 
underlying mechanisms bear distinctive features. c-Myb binds to KIX at the same site as pKID, 
but with 4-25 fold lower binding affinity (values vary between studies based on the length of c-
Myb peptide used and techniques employed).
14,23,28
 Similar to pKID, c-Myb becomes more 
helical upon binding KIX and is proposed to follow a similar folding after binding mechanism.
22
 
However CD studies have shown that there is significantly higher content of helicity in free c-
Myb than in the free pKID peptide.
28
 The driving force of c-Myb binding to KIX is mainly the 





 This further illustrates that elements such as conformational dynamics and interaction 
interface can differentiate two separate ligands binding to the same site of a protein.  
Interestingly, a recent study showed that a potent transcriptional activator HBZ (which binds 
to KIX at the MLL/cJun site) potentiates c-Myb binding by 6-fold, but does not have any 
potentiation effect on pKID.
10
 This supports the hypothesis that c-Myb and pKID bind KIX 
through different modes and are connected by different allosteric networks. This study also 
reveals the fact that different ligands binding at the same site of KIX can have different allosteric 
effects on ligands at the opposite site. However there have not been detailed transient-state 
kinetics studies comparing different allosteric effects on KIX and its binding partners. Our 
studies seek to elucidate the mechanism of a similar situation where small molecule-ligands elicit 
varying allosteric effects on pKID binding to KIX. 
 
B.2. The study of transient-state kinetics of IDP protein-protein interactions  
Protein-protein interactions between intrinsically disordered proteins (IDPs) and their 
binding partners are complicated processes. In addition to electrostatic interactions and hydrogen 
bonding, various other elements must be considered, such as hydrophobic effects and the folding 
of the disordered protein upon binding. This requires not only studying the thermodynamic 
binding affinity of the interaction (KDs), but additionally examining the kinetic properties such as 
transient-state association (kon) and dissociation (koff) rate constants.  
An important characteristic of IDP interactions exemplifies the importance of understanding 
the transient-state kinetics involved: it is widely suggested that IDPs are able to fine-tune 
multiple branching signaling pathways by a combination of high specificity and low affinity.
29–31
 
A closer look at the transient-state kinetics reveals that IDPs are able to achieve this low binding 
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affinity by having extremely high association constants
2,32,33
 (likely due to a larger capture radius 
caused by being structurally flexible)
4,27
 but at the same time also have very high dissociation 
constants.
34
 This short-lived, fast association contributes to the high level of specificity. 
Controversial opinions exist as to whether it is the association or the dissociation rate 
constant that governs the equilibrium binding affinity in IDP interactions. A review by Prakash 
(2011)
35
 found a positive correlation between kon and KD by examining the mutation studies of 
several protein-protein interactions involving IDPs (these rate constants were obtained by either 
SPR or fluorescence stopped-flow experiments).
33,36,37
 However a study by Raza Haq et al 
(2011)
38
 determined that the dissociation rate constant koff governs KD. This was based on 
mutation studies of intrinsically disordered peptides binding to different PDZ domains and the 
rate constants were obtained by FRET stopped-flow. The author argued that in the Prakash paper 
many of the mutations were involved in electrostatic interactions and no mutations that affected 
hydrophobicity were included, hence skewing the results. Clearly further studies on a wider array 
of systems need to be carried out for a more concrete verdict. 
  The work in this chapter takes into consideration the advancements and controversies in the 
field of PPI interaction kinetics, and seeks to establish a model for the kinetic mechanism of 
transcriptional activator-KIX interactions with the tool of a small molecule probe to elucidate the 







C. Experimental Design 
C.1. Selection of TAD constructs 
Nonspecific Binding of Gal4 (1-100) to KIX 
Initial plans involved using a similar setup as outlined in Chapter 2, where Gal4 (1-100) 
would be fused to the TADs of MLL, pKID and c-Myb, and fluorescence intensity of the Gal4-
bound DNA would be monitored upon interaction with KIX. However our initial studies have 
determined that Gal4 (1-100) alone binds to KIX with an affinity of approximately 3-14 μM 
(Figure 4.4). As it is challenging to express Gal4 (1-100) in high quantity without solubility tags, 
both MBP-Gal4(1-100) and GB1-Gal4(1-100) were expressed and both exhibited affinity for 
KIX by fluorescent anisotropy binding assays, ruling out  the possibility that the solubility tag 
contributed to KIX affinity. Gal4 (1-147) was also tested for KIX affinity and showed similar 
affinity to KIX as Gal4 (1-100). Hence we were not able to use this fusion construct to study the 
binding kinetics of various TADs to KIX.  
 
Figure 4.3 Graph of a binding experiment of three Gal4 constructs binding to fluorescein-DNA as a 
control of the integrity and structure of Gal4 DBD. KD values were similar to each other and similar 
to previous experiments as shown in Chapter 2. All measurements were performed in triplicate and 




Figure 4.4 Graph of a binding experiment of three Gal4 constructs in complex with fluorescein-
DNA binding to KIX. All measurements were performed in triplicate and the error bars indicate 
standard deviation (SD). KD was fitted using GraphPad Prism software. 
Use of fluorescently labeled and unlabeled TAD peptides in binding experiments. 
As the Gal4 (1-100)-TAD fusion construct was not feasible to study TAD-KIX interactions,  
peptides derived from the TADs of MLL and pKID were used to monitor the activator-
coactivator interaction, 
7,8
 and fluorescein isothiocyanate (FITC) was coupled to the N-terminus 
of the peptides via a β-Alanine linker (Figure 4.5).  
 
Figure 4.5 a) Sequences of MLL and pKID TADs used in peptide. (* denotes a phosphorylated 
Serine). b) Structure of fluorescein isothiocyanate, where the isothiocyanate group attached to 
fluorescein enables the coupling of FITC to amino acids via an amide bond. FITC was placed at the 
N-terminal of both peptides. 
 
The FITC molecule was placed at the N-terminal of both peptides. A closer look of the 
structure of both MLL and pKID bound to KIX (Figure 4.6) shows that the position of the 
fluorophore will be far away from the binding interface and it will point outward towards 
113 
 
solution. This suggests that the fusion of a hydrophobic fluorophore at this position might 
minimally perturb the binding properties of the peptide TADs. The binding affinity of these 
FITC-TADs to KIX show a similar trend as values published by other groups (Figue 4.12). 
Moreover, these results are also within 10-fold difference of the values obtained by isothermal 
titration calorimetry (ITC) without any tags on the components.
7,9,18
 Nonetheless, to avoid any 
inconsistencies, the absolute kinetics values obtained in this work are only compared with other 
values that are obtained with FITC-TADs. 
 
Figure 4.6 Position of FITC relative to the TAD-KIX complex. a) FITC (yellow circle) at N-
terminus (labeled yellow) of MLL (red) in the MLL-KIX (grey)-c-Myb complex (PDB 2AGH). b)  
FITC (yellow circle) at N-terminus (labeled yellow) of pKID (blue) in the pKID-KIX (grey) 
complex (PDB 1KDX). Helices α1, α2 and α3 are labeled for clarity. 
 
C.2. Complexes of KIX used in binding experiments. 
Apart from free KIX and KIX in complex with excess amounts of MLL peptide, additional 
complexes of KIX mutants tethered to small molecule fragments were also used to study the 
kinetics of allosterically perturbed KIX binding to pKID.  
  The cysteine mutants KIX N627C and KIX L664C (Figure 4.8) were used in this study 
based on their high affinity to fragment 1-10 (as quantified by Dose Response DR50, see Chapter 
3). In addition, KIX L664C also has affinity to a larger fragment 2-64 (Figure 4.7). The integrity 
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of these two mutants compared to KIX wt was determined by circular dichroism scans (data not 
shown) and binding affinity to MLL and pKID as shown in Figure 4.12 .  
 
Figure 4.7 Structures of fragments 1-10 and 2-64 that emerged from a disulfide screening library as 
tethering fragments to KIX at the MLL binding site. 
 
Figure 4.8 Position of mutations L664C and N627C on KIX (grey) and their relative orientation 




D.1. Stopped-flow of MLL and pKID binding KIX 
The transient-state binding kinetics between KIX and MLL or pKID was examined by 
fluorescence stopped-flow.  
25 nM of pKID-FITC was rapidly mixed with either KIX storage buffer (10 mM Sodium 
Phosphate, 100 mM NaCl, 0.01 % NP-40, 10 % Glycerol, pH 6.8) (Figure 4.9a) to control for 
potential photo bleaching of the fluorophore or 0.1mg/ml of BSA in KIX storage buffer (Figure 
4.9b) to control for effects of nonspecific binding and crowding of protein. Both control 
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experiments revealed no change in fluorescence intensity over a 120 second time period. Similar 
controls were carried out for MLL-FITC with similar results (data not shown). 
 
Figure 4.9 Stopped-flow traces of control experiments a) 25 nM pKID-FITC rapidly mixed with 
KIX storage buffer and b) 25 nM pKID-FITC rapidly mixed with 0.1 mg/ml BSA in KIX storage 
buffer. Both spectra obtained by excitation at 493 nm and emission collected with a 510 (LP) filter. 
Both spectra are an average of 5-8 separate traces. 
25 nM of MLL-FITC or pKID-FITC in KIX storage buffer was rapidly mixed with excess 
amount of KIX complexes at varying concentrations of 0.25-5 μM in KIX storage buffer. The 
resulting change in fluorescence intensity (Figure 4.10) was monitored over several time periods 
varying from 0.05 seconds to 120 seconds. Two phases were observed for both MLL and pKID 
binding to KIX. However the faster phase of the MLL-KIX interaction took much less time to 
complete (0.05 seconds) as compared to the slower phase (120 seconds), so two different time 
domains were used to monitor the interaction, and each trace was fit to a monophasic equation. It 
was possible to record both time domains for the pKID-KIX interaction in one single trace, 
which were then fit to a biphasic equation to obtain kobs (See Experimental methods section for 




Figure 4.10 Representative stopped-flow traces of a) association of MLL with KIX, a shorter time 
domain to observe the fast phase (0.05 sec) and a longer time domain to monitor the slow phase 
(120 sec) and b) association of pKID with KIX, using a split time domain to capture both the fast 
phase (5 sec) and the slow phase (120 sec). All spectra were obtained by excitation at 493 nm and 
emission collected with a 510 (LP) filter. All spectra are an average of 3-5 separate traces. 
 
Both peptides bind to KIX via a two-step mechanism, similar to observations made in 
previous studies (chapter 2) of Gal4, Gcn4 and VP16 TADs binding to Med15.
1
 The observed 
rate of the fast phase linearly correlates with KIX concentration, suggesting a bi-molecular 
association step, while the observed rate of the slower phase does not exhibit positive linear 
correlation to KIX concentration (Figure 4.11). The slope value from linear regression fits of 
observed rate constant plotted over KIX concentration are the on-rates (kon) of the association 





with values obtained by NMR relaxation dispersion in literature (6.3 μM-1s-1).2 The on-rate of 




). Further studies will focus on 




Figure 4.11 Observed association rate of a) the fast phase (kobs,1) and b) the slow phase (kobs,1) of 
the MLL/pKID-KIX interaction plotted against KIX concentration. The slow phase was not 
observable at high KIX concentrations in the pKID-KIX interaction. The error bars represent the 
error of the fitted kobs values for the average (of 3-5) traces per KIX concentration point. 
 
D.2. Cooperativity of MLL and pKID binding to KIX  
In agreement with literature,
7,9
 fluorescent anisotropy experiments have shown that KIX will 
bind to the pKID peptide with higher affinity if it is pre-complexed with excess amounts of MLL, 
and vice versa (Figure 4.12a). By incubating KIX with various molar equivalents of either MLL 
or pKID unlabeled peptide and monitoring the dissociation constant (KD) of this complex with a 
FITC (fluorescein isothiocyanate)-labeled pKID or MLL peptide, we can conclude that 4 molar 
equivalents of MLL or pKID peptide pre-complexed with KIX is enough to elicit the 





Figure 4.12 Cooperativity between MLL and pKID binding to KIX a) Anisotropy binding curves of 
KIX binding to either MLL or pKID when pre-complexed with indicated molar equivalents of the 
other TAD peptide. All measurements were performed in triplicate and the error bars indicate 
standard deviation (SD). b) Graph of KDs from GraphPad Prism fits of curves in a) plotted over 
molar equivalents of the other TAD peptide shows the extent of cooperativity is “saturated” when 
approximately 4 molar equivalents of both MLL and pKID is pre-complexed with KIX, error bars 
represent the standard error of non-linear fit in Prism. 
 
D.3. The allosteric effect of 1-10 tethering on the pKID binding affinity of different KIX mutants 
To assess the allosteric effect of 1-10 tethering to either KIX N627C or KIX L664C, the 
equilibrium dissociation constants of 1-10—KIX N627C and 1-10—KIX L664C and the pKID-
FITC peptide were recorded. pKID binds to the opposite allosteric site of KIX that 1-10 is not in 
direct contact with. Equilibrium constants were obtained by fluorescent anisotropy binding 
assays. These dissociation constants were compared to that of two other KIX complexes: free 
KIX mutants with pKID-FITC, and when 4 molar equivalents of MLL were pre-complexed with 




Figure 4.13 Anisotropy binding curves of complexes of KIX wt, KIX N627C and KIX L664C 
binding to pKID. All measurements were performed in triplicate and the error bars indicate standard 
deviation (SD) of the three measurements.  
 
Table 4.1 Summary of KD values from GraphPad Prism fits of binding curves in Figure 4.13. Errors 
reflect the standard error of non-linear fits in Prism. 
KIX construct Free with 4xMLL tethered to 1-10 tethered to 2-64 
KIX wt 0.72 ± 0.14 μM 0.50 ± 0.08 μM NA NA 
KIX N627C 0.82 ± 0.05 μM 0.62 ± 0.08 μM 0.60 ± 0.09 μM NA 
KIX L664C 0.46 ± 0.04 μM 0.50 ± 0.04 μM 1.12 ± 0.08 μM 0.49 ± 0.11 μM 
 
In summary, the tethering of 1-10 to KIX N627C seems to have similar allosteric effects on 
KIX as that of 4 molar equivalents of MLL in terms of the increase of pKID affinity. This is 
highly intriguing that a small molecule can cause similar allosteric effects as a 19-residue peptide. 
1-10 tethered to KIX L664C on the other hand abrogates pKID binding to KIX. Interestingly, 
while KIX N627C shows similar potentiation of pKID affinity by MLL as that of KIX wt, no 
such potentiation is observed when MLL is pre-complexed with the KIX L664C mutant. This 
suggests that certain components of the allosteric network might be disrupted upon the mutation 
at Leu 664. This observation is consistent with that of previous studies (dissertation work from 
Sven Brüschweiler) where the mutation of Ile 660 to Val, a residue close to Leu 664, resulted in 




D.4. Stopped-flow spectroscopy of different states of KIX binding to pKID  
Stopped-flow fluorescence spectroscopy was applied to compare the transient-state kinetics 
effects of KIX complexed with either MLL or small molecule tethering fragments.  Association 
and dissociation stopped-flow fluorescence assays were carried out by monitoring the 
fluorescence intensity of fluorescein isothiocyanate (FITC) at the N-terminus of the pKID 
peptide when pKID is either a) rapidly mixed with KIX (association) or b) competed off KIX 
with excess amounts of unlabeled pKID peptide (dissociation).  
 
Figure 4.14 Representative stopped-flow traces of a) association of pKID with various KIX 
complexes and b) dissociation of pKID from KIX complexes by competition of excess amounts of 
unlabeled pKID peptide. All spectra were obtained by excitation at 493 nm and emission collected 
with a 510 (LP) filter. All spectra are an average of 5-8 separate traces. 
 
For direct association binding assays, 25 nM of pKID-FITC (after mixing) was rapidly mixed 
with excess amount of KIX complexes (free protein, pre-complexed with 4 equivalents of MLL 
peptide, pre-tethered with 1-10 or 2-64) at varying concentrations of 0.1-5 μM (after mixing). 
The resulting change in fluorescence intensity (Figure 4.14a) was monitored over several time 
periods varying from 0.05 seconds to 10 seconds and fit best to a single exponential equation to 
obtain kobs (See Experimental methods section for detailed description).  
For dissociation assays, 25 nM of pKID-FITC in KIX storage buffer was pre-equilibrated 
with 500 nM KIX complex and rapidly mixed with 12.5 μM (500 molar equivalents) of 
unlabeled pKID peptide in KIX storage buffer. The resulting change in fluorescence intensity 
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(Figure 4.14b) was monitored over several time periods varying from 0.1 second to 10 seconds 
and fit best to a single exponential equation to obtain kobs (See Methods section for detailed 
description). The time domain of 1 second was selected for data analysis as it was closest to the 
predicted best time-frame by the fits in the Kintek software.   
The observed rates obtained from fitting the association spectra were plotted against KIX 
concentration and displayed a linear relationship to KIX concentration (Figure 4.15). The slopes 
of the linear regression fits are the overall on-rate of pKID interacting with KIX as summarized 
in Table 4.2. The observed rates obtained from fitting the dissociation spectra are the off-rates of 
pKID being competed off KIX complexes, summarized in Table 4.3. 
 
Figure 4.15 kobs of pKID binding to KIX complexes plotted against KIX concentration for KIX wt, 
KIX N627C and KIX L664C. Each data point is an average of the  kobs of two separate experiments; 
each experiment is an average of five to eight traces. The error bars represent the standard deviation 
of the two separate kobs values. 
Table 4.2 On-rates of pKID binding to KIX complexes from the slopes of linear regression fits of 





) Free with 4xMLL tethered to 1-10 tethered to 2-64 
KIX 14 ± 1 14 ± 1 NA NA 
KIX N627C 15 ± 1 14 ± 1         17 ± 2 NA 
KIX L664C 23 ± 2 24 ± 2 6 ± 1 20 ± 2 
 
Table 4.3 Off-rates of pKID dissociating from KIX complexes. Errors are standard deviations of the 
average of two separate values. 
koff  (s
-1
) Free with 4xMLL tethered to 1-10 tethered to 2-64 
KIX 7.0 ± 0.4 5.0 ± 1.3 NA NA 
KIX N627C 7.3 ± 1.3 4.1 ± 2.5 4.0 ± 0.8 NA 
KIX L664C 8.7 ± 0.4 7.7 ± 0.3 13.8 ± 0.6 10.2 ± 3.5 
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Comparison of the on and off rates between pKID and various KIX complexes similar trends 
among KIX complexes between transient-state off-rates and equilibrium binding constants 
(Figure 4.16). Also of interest is while most of the on-rates are similar for all KIX complexes 
binding to pKID, 1-10—KIX L664C seems to have an exceptionally slow on-rate. This could be 
related to the fact that 1-10 tethering is hindering the flexibility of the KIX protein and thus 





Figure 4.16 a) Bar graph of equilibrium binding constants of pKID binding to KIX complexes. b) 
Bar graph of on-rate of pKID binding to KIX complexes. c) Bar graph of off-rate of pKID 
dissociating from KIX complexes. The error bars represent standard deviation of the average of two 
values from separate experiments. 
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D.5. Φ values for 1-10—KIX N627C and 1-10—KIX L664C suggest 1-10 elicits different 
allosteric effects when tethered at different positions 
Φ values were calculated for 1-10—KIX N627C and 1-10—KIX L664C, the two small 
molecule-KIX complexes that notably altered KIX affinity to pKID, to further investigate the 
observation that 1-10 is having different effects on different KIX mutants.  
Φ value analysis was applied to examine the roles of specific amino acids during the 
transition state of protein folding.
39
 It has been shown that this analysis can also be more broadly 
applied to study the transition state of protein-protein association.
40–44
 In Φ value analysis, the 
change in free energy for the binding association kinetics upon mutation (ΔΔG
‡
) is related to the 
change in free energy for the overall binding reaction (ΔΔG
eq
), calculated by the following 
equations: 
                                       (Eq. 4.1) 
where  
           
   
  
   
       (Eq. 4.2)            and        




         (Eq. 4.3) 
A Φ value of 1 means that the mutations/changes on the protein have an effect on the 
transition state of the interaction, indicating that the change in KD is governed by the change in 
kon. A Φ value of 0, on the other hand, means the mutations/changes have an effect after the 
transition state of the interaction, indicating that the change in KD is governed by the change in 
koff. While Φ value analysis is usually used to study the effect of single-residue mutations on 
protein-protein interactions,
38,45,46
 in this study we employ it to examine the effect of the tethered 
small molecule 1-10 on KIX-pKID interaction. The results are shown in Table 4.4. It shows 1-
10—KIX N627C with a low Φ value, suggesting the 1-10 tethering is having an effect on the 
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interaction after the initial bimolecular association step. 1-10—KIX L664C however displays a 
much larger Φ value, indicative of effects occurring during the initial association step.  



























1-10—KIX N627C 16.6 ± 1.8 -0.056 0.60 ± 0.09  -0.19 0.3 
1-10—KIX L664C 6.3 ± 1.1 0.766 1.12 ± 0.08  0.53 1.4 
 
E. Discussion and Conclusions     
Overall, these transient-state kinetic analyses suggest the KIX-pKID interaction undergoes at 
least two steps: a fast bi-molecular association step and a slow conformational change step. 
Using the available data it is not possible to distinguish if the conformational change step occurs 
before or after the bi-molecular association step. However based on literature results 
1,2,22,25
 and 
for ease of discussion, the mechanism FreeIntermediateBound will be employed to 
demonstrate key conclusions. As shown earlier in Figure 4.2 and in literature
2
, there might be an 
even faster phase between the Free and Intermediate states, but similar to the NMR relaxation 
dispersion data used in literature, this phase is not observable under stopped-flow conditions. 
Hence the following discussion will address the FreeIntermediate overall interaction as one 
step.  
The bar graphs of KD and koff values in Figure 4.16 (a) and (c) show a similar trend across 
different KIX complexes. This suggests that there is a positive correlation between the change in 
KIX’s affinity to pKID (KD) and the dissociation rate of pKID from KIX (koff). This phenomenon 
has been observed before in studies on both protein-protein interactions involving disordered 
proteins
38,45
 and protein-protein interactions involving structured proteins.
35
 The way our 
stopped-flow experiment is set up means that kon only reflects the on-rate of the bimolecular 
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association step, but koff reflects the overall off-rate of pKID from KIX including both the 
conformational change step and the biomolecular dissociation step. The fact that koff  is governing 
KD suggests that the changes in KIX (complex with MLL or small molecule) are affecting the 
slow conformational change step of the interaction by eliciting allosteric effects on the pKID 
binding site. 
Equilibrium association values and 
Φ value analysis of 1-10 tethered to 
KIX N627C and KIX L664C binding to 
pKID show that the same small 
molecule is eliciting different allosteric 
effects on the distal pKID binding site. 
As mentioned in the results section and 
demonstrated in Figure 4.17, when Φ is 
close to 0, as in ΔΔG
‡ 
is much smaller 
than ΔΔG
eq
, it means that 1-10 tethering 
is affecting side chain involved in steps 
occurring after the transition state, and 
vice versa when Φ is close to 1. The Φ value for 1-10—KIX N627C is 0.3, which is in the low to 
mid range
45
, whereas Φ for 1-10—KIX L664C is 1.4, which is a much higher value. This is 
suggesting that when tethered to KIX N627C, 1-10 allosterically affects KIX amino acid side 
chains that are involved in the conformational change step in KIX-pKID binding, whereas it is 
affecting KIX side chains that are involved in the bimolecular association step of the KIX-pKID 
interaction when tethered to KIX L664C. Projecting further in the future, the fact that a same 
 
Figure 4.17 Energy diagram of the KIX-pKID 
interaction, depicting the free energy of association 
kinetics (ΔG
‡







small molecule can elicit entirely different and even opposite allosteric effects on the same 
binding site of a protein when tethered at different positions suggests the potential of using small 
molecules as a switch in cells. One could foresee changing the cellular environment, by pH, 
temperature or excitation wavelength, and being able to change to property of a small molecule 
to either up regulate or down regulate a certain pathway. 
In conclusion, we have performed fluorescence stopped-flow assays to study the transient 
state kinetics of various KIX constructs binding to TADs pKID and MLL. We observed that 
MLL and pKID bind to KIX through a similar two-step mechanism as that of TADs binding to 
Med15: a rapid bimolecular association step and a slower conformational change step. We find 
that small molecule fragment 1-10 can elicit allosteric effects on KIX at the distal pKID binding 
site with the same order of magnitude as a known peptide ligand MLL. In addition we show that 
the off-rate (koff) of these interactions is the driving force of the change in equilibrium binding 
affinity (KD) between KIX and pKID. More importantly, we show that 1-10 can allosterically 
affect different sets of amino acids in KIX depending on the position of the tethering. One set of 
these residues are more involved in the association of KIX and pKID, while the other set is more 
involved in the conformational change step of KIX-pKID interaction. As a result the same 
molecule can either enhance or abrogate the affinity of KIX to pKID when at different positions, 
some of which are different effects from that elicited by the native peptide ligand MLL. These 
results provide insight into the exciting potential of using small molecules as powerful probes in 
dissecting the allosteric mechanisms of protein-protein interactions in ways native peptide 




F. Future Directions 








C HSQC NMR of both 1-10—KIX L664C and 1-10—KIX 
N627C as well as 2-64—KIX L664C would provide more direct structural information on the 
allosteric effects of small molecules on KIX. Comparing the chemical shift of the tethered KIX 
constructs to free KIX would define which specific residues are perturbed by the small molecules 
in different positions. A complementary method would be to try and obtain crystal structures of 
1-10—KIX N627C and 2-64—KIX L664C. While one would not be able to compare these 
structures to that of free KIX, one could however see the differences in side chain interactions 
between the different small molecules at different positions on KIX. This can identify in detail 
what residues are important for KIX-pKID association and what residues are important for the 
coupled folding conformational change occuring with binding. 
 
F.2. FRET or fluorescence quenching stopped-flow 
The fluorescence probe FITC used in this study displayed a change in fluorescence intensity 
upon TAD-KIX binding, likely due to changes in the local environment of the fluorophore. 
While we were able to glean kinetic constants from this change, we were not able to directly 
observe more details such as the difference in distance between TAD and KIX over time. 
Installing a small non-invasive FRET pair on the pKID or c-Myb TAD and KIX will enable 
higher resolution read-outs of the interaction as well as conformational change. Strategically 
placed small molecule FRET pairs such as Cy3 and Cy5 will directly reflect changes in distance 
by change in FRET efficiency and act as a molecular ruler.
47
 Similarly, a fluorophore and a 
quenching molecule can achieve the same purpose. The real-time change in FRET or quench 
129 
 
efficiency will aid in accurately identifying which steps are association (large change in distance 
and efficiency) and which steps are conformational changes (smaller changes in distance and 
efficiency).
48–51
 This will enable us to propose a more detailed mechanism scheme for TAD-KIX 
association and the effects of small molecule tethering to KIX. 
 
G. Experimental Methods 
Protein Expression and Purification 
As previously described,
14
 the DNA sequence encoding the KIX domain of mouse CBP 
(586-672) was cloned into a pRSETB vector incorporating a hexahistidine tag with a short linker 
fused to the N-terminus of KIX for protein expression resulting in a protein with sequence (tag 
and linker residues are shown in lower case):  
mrgshhhhhhgmasGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKDRRMENLV
AYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRL  
The cysteine mutant at KIX L664C was created using site-directed mutagenesis as previously 
described.
14
For protein expression, the plasmid was transformed into Rosetta2 (DE3) pLysS E. 
coli (Novagen) and grown in LB media. After an O.D.600 of 0.8 was reached (37 °C, 250 rpm), 
the cultures were cooled to 25 °C and expression was induced with 0.5 mM IPTG for 4 h (250 
rpm). The His-tagged protein was isolated using Ni-NTA beads (Qiagen) according to the 
manufacturer’s instruction and eluted with 400 mM imidazole.  Final purification was carried out 
by ion-exchange column chromatography on a Source S column, (GE Healthcare) in 50 mM 
phosphate buffer, 1 mM DTT, pH 7.2 eluting with increasing concentrations of NaCl (0-1 M 
NaCl).  Purified protein solutions were buffer exchanged into 10 mM sodium phosphate, 100 
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mM NaCl, 10 % glycerol 0.01 % NP40, pH 6.8 using a PD-10 column (GE-Healthcare) and 
stored at -80 °C.   
 
Peptide Synthesis and Purification 
All peptides were synthesized by standard N-9-Fluorenylmethoxycarbonyl (Fmoc) solid 
phase synthesis methods
1
 on CLEAR amide resin (Peptide International, 0.48 mmol/g). In the 
case of MLL15 and Myb25, a c-terminal tyrosine or tryptophan were added respectively to 
facilitate concentration determination. All peptides were cleaved from the solid support in a 
mixture of 95/2.5/2.5 trifluoroacetic acid (TFA)/triisopropylsilane/water for 3-4 hrs followed by 
evaporation of solvent under a nitrogen stream except for Myb25 and Fl-Myb25 which were 
cleaved in 92.5% TFA 2.5% thioanisole and 2.5% ethanedithiol followed by addition of TMS-
bromide during the last 15 minutes of cleavage to prevent methionine oxidation. The crude 
peptides were precipitated into cold ether and purified by reverse phase HPLC on a Waters C18 
column using water with 0.1% TFA as the A solvent and CH3CN as the B solvent.  Product 
molecular weight was confirmed by electrospray ionization mass spectrometry (ESI-MS) using a 
Micromass LCT Time-of-Flight mass spectrometer. 
 
Peptide Sequence ESI-MS 
Mll19 AcWADAGILPSDIMDFVLKNTYCONH2 Calculated M-1: 2310    
Experimental ES-  
m/1 = 2309.4  
Fl-Mll19 FITC-beta-ADAGNILPSDIMDFVLKNTPCONH2,  
 
Calculated M-1: 2517 
Experimental ES-:  






Calculated M+1:3480  
Experimental ES+:  




Table 4.5 Peptide sequence and ESI-MS characterization 
Fragment Tethering 
KIX L664C  or KIX N627C was incubated with 10 equivalents of 1-10 or 2-64 in 50 mM 
phosphate buffer at pH 6.8 overnight, excess small molecule was removed by NAP-5 desalting 
column and buffer exchanged into 20 mM HEPES, 100 mM NaCl, pH 8.0. Small molecule 
tethering efficiency was confirmed by Q-TOF LC-MS (Agilent) and tethering reached at least 95% 
complete. Protein-small molecule complexes were flash frozen in liquid N2 and stored at -80°C. 
 
Fluorescent Anisotropy Assays 
The fluorescent anisotropy assays were done in triplicate with a final sample volume of 10 
μL in a low volume, non-binding, black, 384-well plate (Corning), and read using a Tecan 
Genios Pro plate reader with polarized excitation at 485 nm and emission intensity measured 
through a parallel and perpendicularly polarized 535 nm filter. FITC (Fluorescein isothiocyanate) 
labeled peptides were diluted in storage buffer (10 mM Phosphate, 100 mM NaCl, 0.01 % NP-
40, 10 % Glycerol, pH 6.8) to a concentration of 25 nM. Then 10 µL of the peptide solution was 







Calculated M+1: 3972 
Experimental ES+:  







Calculated M-1:  3169 
Experimental ES-:  







Calculated M-1: 3587  
Experimental ES-:  
m/2 = 1792.5  
(M-1;3586);  
ES-m/3 = 1195.0  
(M-1; 3587) 
All single letter amino acid abbreviations are use unless indicated:  beta-A (beta-alanine), AEEA (2-
(2-amino-ethoxy)-ethoxy acetic acid, S (phos) (phosphoserine). 
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final concentrations of up to 20 μM. The samples were incubated for 30 min at room temperature 
before the degree of fluorescence anisotropy was measured (Tecan Genios Pro). Anisotropy data 
was corrected for change in fluorescence intensity using Equation 4.4. 
 
A binding isotherm that accounts for ligand depletion (assuming a 1:1 binding model of 
peptide to GACKIX) was fit to the observed anisotropy values as a function of KIX to obtain the 
apparent equilibrium dissociation constant, KD: 
  
where “a” and “x” are the total concentrations of fluorescent peptide and KIX, respectively, “y” 
is the observed anisotropy at any KIX concentration, “b” is the maximum observed anisotropy 
value, and “c” is the minimum observed anisotropy value. Each data point in figures in Results 
section is an average of three independent experiments with the indicated error (standard 
deviation). Data analysis was performed using GraphPad Prism 5 software.  
 
Fluorescence Stopped-Flow Kinetic Assays 
Stopped-flow experiments were performed on a KinTek model SF-2001 stopped-flow 
equipped with a 75W Xe arc lamp in two-syringe mode. FITC was excited at 493 nm and its 
emission was monitored at wavelengths > 510 nm using a long-pass filter (Corion). 
Association Experiments: 25 nM (final concentration after mixing) of pKID-FITC in KIX 
storage buffer was rapidly mixed with excess amount of KIX complexes (free protein, pre-





concentrations of 0.1-5 μM (final concentration after mixing) in KIX storage buffer at 25°C. The 
time domains (0.1 and 1 second or 0.05 and 0.5 second for fast phase and 120 sec for slow phase) 
were selected for data analysis as they were closest to the predicted best time-frame by the fits in 
the Kintek software.   
Dissociation Experiments: 25 nM (final concentration after mixing) of pKID-FITC in KIX 
storage buffer was pre-equilibrated with 500 nM KIX complex (final concentration after mixing)  
and rapidly mixed with 12.5 μM (500 molar equivalents, final concentration after mixing) of 
unlabeled pKID peptide in KIX storage buffer at 25ºC.  
All kinetic traces reported are an average of five to eight independent determinations. Sum of 
exponentials was fit to the transient kinetic time courses, F (t) as in Equation 4.6, to obtain the 
fluorescence amplitude (A) and the observed rate, kobs, for each exponential phase where F (0) is 
the initial fluorescence intensity, and t, time: 
 
Two control experiments were performed to ensure that the fluorescence changes are from a 
KIX-pKID interaction: 25 nM of pKID-FITC was rapidly mixed with either KIX storage buffer 
(10 mM Sodium Phosphate, 100 mM NaCl, 0.01 % NP-40, 10 % Glycerol, pH 6.8) or 0.1mg/ml 
of BSA in KIX storage buffer at 25ºC. Both control experiments exhibited no time-dependent 
change in fluorescence intensity over a 10 second time period. 
Analysis of the time courses was performed using Kintek software, and the reported errors 
are the asymptotic standard errors. The dependence of the observed rates on KIX concentration 
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Chapter 5 Conclusions and Future Directions 
A. Conclusions 
In this dissertation, the experiments have resulted in furthering our knowledge of the 
mechanism of transcriptional activator-coactivator interactions, a process that has been studied 
for several decades but is still not completely understood. Particularly, various biochemical and 
biophysical methods were applied to the study of two different activator-coactivator systems: the 
TADs VP16, Gal4 and Gcn4 and their shared coactivator Med15, and a more conformationally 
defined system which is the TADs MLL and pKID and their shared coactivator the KIX domain 
of CBP. We have detailed the transient-state kinetics characteristics of these activator-coactivator 
interactions, and have determined the effects on the activator-coactivator interaction and 
coactivator conformation when covalently tethering a small molecule to the coactivator.  
 
A.1. Transient-state kinetic mechanisms of activator-coactivator interactions 
In Chapters 2 and 4, transient state kinetic analysis has established that the mechanisms for 
both the TAD (VP16, Gal4, Gcn4)-Med15 interaction and the TAD (MLL, pKID)-KIX 
interaction are at least biphasic, involving a fast, bimolecular association step and a slow, 
conformational change step (Figure 5.1).  
We have compared the kinetic properties of different TADs (VP16, Gal4 and Gcn4) binding 
to the same coactivator (Med15)
1
  in Chapter 2 and different complexes of a coactivator (KIX 
with MLL or small molecules) binding to the same TAD (pKID) in Chapter 4.  
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In both cases, there is a strong correlation between the overall binding affinity and the slow 
conformational change step. This suggests that conformational flexibility plays a key role in the 
ability of both activators and coactivators to distinguish between different binding partners by 
varying the overall binding affinity. There has been similar observations in literature regarding 
the multispecificity of hub transcription factors by examining their structural characteristics.
2–7
 In 
this study, a unique kinetic approach has been taken to address and confirm such a correlation. 
The further understanding of this interaction mechanism will enable better guided designs of 
small molecule modulators of activator-coactivator interactions in the future. By tuning the 
extent of flexibility of a small molecule we might be able to control the binding affinity of that 
molecule to transcriptional activators or coactivators, hence control the potency of the small 
molecule. 
 
Figure 5.1 Schematic of the activator-coactivator interaction mechanism. A fast bimolecular 
association step is coupled with a slower conformational change step. 
 
A.2. Allosteric effects of a small molecule modulator on activator-coactivator interactions 
The work outlined in this dissertation has also demonstrated the potential of using a small 
molecule modulator to probe transcriptional activator-coactivator interactions.  A small molecule 
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fragment 1-10 emerged from a Tethering 
screen against the MLL binding site of 
KIX. In Chapter 3, we were able to obtain 
a homogenous crystal of 1-10—KIX 
L664C, and solved the first crystal 
structure of the KIX domain of CBP.
8
 
This enabled us to have a closer look at 
various side chain orientations and 
examine the structural shifts in KIX, 
specifically the loop region, in its different 
complexes. In Chapter 4, we have also 
been able to use 1-10 to allosterically 
modulate the affinity of KIX to pKID at a distal binding site, and used this as a tool to study the 
correlation between transient state kinetics and equilibrium binding affinity as outlined above. 
More importantly, we discovered that the same small molecule 1-10 can have different allosteric 
effects depending on what position it is tethered to on KIX (Figure 5.2). While 1-10 tethering to  
KIX N627C seemed to affect the residues governing conformational change after pKID binding 
(similar to the effect of MLL), 1-10 tethering to KIX L664C affected residues governing the 
initial bimolecular association of pKID to KIX. As a result the same molecule can either enhance 
or abrogate the affinity of KIX to pKID when at different positions. This enabled us to use 1-10 
to examine allosteric effects on KIX that MLL was not able to elicit. Furthermore, this provides 
important insight into the possible consequences of the application of small molecule modulators. 
It reveals the potential of designing a small molecule as a transcriptional “switch”, where a 
 
Figure 5.2 Structure of 1-10—KIX L664C (PDB 
4I9O). N627C is labeled as well. This snapshot 
shows that the two mutations, L664C and N627C 
are at opposite sides of the MLL binding site and 
on different helices. This possibly contributes to 





certain extracellular signal, such as change in pH or oxidation state can convert a transcriptional 
repressor to a transcriptional activator and vice versa.  
 
B. Future Directions 
B.1. Application of environmentally sensitive fluorophores 
In Chapters 2 and 4, fluorescein was utilized as the fluorescent probe to detect changes in the 
local environment upon binding. While we were able to glean useful data from this, the 
amplitude of intensity change was quite low, ranging from 5-20% of the initial fluorescence 
intensity (see Figures 2.9, 2.10 and 4.10, 4.14). This results in lower signal to noise resolution 
and we might miss or misinterpret certain steps. A simple solution to this is to use 
solvatochromic fluorophores instead. Solvatochromic fluorophores can be extremely useful in 
monitoring protein-protein interactions.
9–11
 These are environmentally sensitive fluorophores that 
have low quantum yield when exposed to polar solvents such as water, and have up to 100-fold 
higher quantum yield when buried in hydrophobic environments.
12–14
  
Labeling either the more structured coactivator or the unstructured activator with such a 
fluorophore could provide higher resolution data reflecting the binding interaction (Figure 5.3). 
By labeling the binding site of a coactivator such as KIX with a solvatochromic fluorophore, one 
can directly monitor the conformational changes on KIX instead of the activator TAD. This will 
be more applicable to testing the hypothesis that small molecules are potentiating pKID binding 
to KIX by changing the conformation of KIX so less conformational change is required upon 
pKID binding (Figure 5.3a). By labeling an activator that transitions from unstructured to 
structured upon coactivator binding, such as c-Myb, pKID, HBZ or Gal4, one can obtain 
information regarding the formation of a helix upon binding.
11
 This is especially advantageous to 
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monitoring TADs such as c-Myb that do not display N-terminal FITC fluorescent intensity 
change upon KIX-binding (Mapp lab, data unpublished) as well TADs that do not have a defined 




Figure 5.3 Schematic of utilizing solvatochromic fluorophores to monitor activator-coactivator 
interactions in two ways. a) The fluorophore is tagged on the more structured coactivator at the 
binding site, upon binding of an activator, the coactivator undergoes conformational change, 
resulting in the fluorophore being buried in a more hydrophobic environment and emission increases. 
b) The fluorophore is tagged on the unstructured TAD, upon the TAD assuming a helical structure 
after binding to a coactivator, the fluorophore is buried in the hydrophobic core of the helix and 
emission increases. 
 
While there are several commercially available solvatochromic fluorophores, such as MDCC, 
IANBD, BADAN, IAEDANS and PyMPO, a fluorophore developed by the Imperiali group is 
especially attractive for this purpose. 4-N,N-dimethylamino-1,8-naphthalimide (4-DMN) has 
been shown to be superior to several commercially available solvatochromic fluorophores due to 
its low background signal, large increase in quantum yield upon protein binding/folding, long 
excitation wavelength (408 nm) deeming it more bio-orthogonal, and high stability in aqueous 
solution.
16,17
 In addition, the protocols are available for synthesizing versions of this fluorophore 
for both solid phase peptide synthesis incorporation and cysteine-labeling,
13,18
 so one can 





B.2. In cell NMR 
As multiple studies have shown, the inner cellular environment is extremely crowded (Figure 
5.4). Estimations suggest that the protein concentration in a living cell is 200-300 mg/ml, while 
the RNA concentration is 75-150 mg/ml, in total these proteins and nucleic acids may occupy up 
to 40% of the intracellular environment.
19–21
 This crowding effect can mean that the structural 
characterizations of intrinsically disordered proteins are different in cells than that in a dilute 
homogenous buffer.
22,23
 This also holds true for the protein-protein interactions. The high 
viscosity can limit rotational diffusion of proteins and alter the binding kinetics.
24
  
  To address this shortcoming of studying protein interactions in buffer, in cell NMR  has 
been developed to examine the conformation of proteins in a cellular environment in the context 
of Xenopus oocytes, Escherichia coli and 
mammalian cells.
25–30
 A method has also been 
described to monitor protein-protein interactions in 
cells (STINT-NMR),
31
 and has been applied to 




In cell NMR will be a powerful tool for 
studying the conformational dynamics of 
disordered TADs undergoing the binding 
interaction with coactivators, such as Gal4 and 
Med15 or its suppressor Gal80. We are already 




N HSQC spectra of GB1 
tagged Gal4 TAD (residues 840-881, see 
 
Figure 5.4 Artistic representation of a 
cross-section of a small portion of an E. 
coli cell. The cell wall and a flagellar 
motor are in green, the cytoplasmic area 
includes enzymes (blue) and ribosomes 
(purple) with RNA depicted in white. The 
nucleoid region is shown in yellow and 
orange. Illustration reproduced with 
permission by David S. Goodsell, the 




Appendix). This suggests there is potential in pursuing in cell NMR on this construct and 
monitoring its protein-protein interactions by collaborating with highly established NMR 
laboratories on campus such as the Al-Hashimi lab. Also, a simpler and faster 
19
F-NMR 
technique to study the basic conformational dynamics of KIX has been developed in the Mapp 
lab,
33
 this can be adapted to in cell NMR methods as well, enabling us to monitor the interactions 
of KIX with its various ligands in a cellular environment. 
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Many transcriptional activators are intrinsically disordered proteins or have intrinsically 
disordered domains.
1–6
 This enables allosteric interactions between domains and between 
binding partners, giving these proteins the advantage of multispecificity.
7–9
 However this unique 
characteristic does impede the understanding of these proteins and their interactions on a 
structural level, as it is more difficult to obtain a structure or ensemble of conformations using 
traditional structural techniques such as protein crystallography. Nuclear Magnetic Resonance 
(NMR) has proved to be a powerful tool in detecting the conformation of more structurally 
flexible proteins.
10–13
 Gal4 has been studied as a prototypical eukaryotic transcriptional activator 
for several decades,
14–17
 and is involved now in routine systems used to probe transcriptional 
pathways in cells.
18,19
 However the structural details of Gal4 remain vague, and additional 
information is crucial in fully understanding the mechanism of this activator. Here, using 
structural information gained by NMR spectroscopy, we are able to investigate the allosteric 
effects between two Gal4 domains, the DNA binding domain (DBD) and the transcriptional 
activation domain (TAD). This can aid in further understanding of Gal4 when used as a probing 
tool, as well as provide insight into the structural information on transcriptional activators in 
general. 
 
                                                 
9
 This work was performed in collaboration with Amanda Dugan and Felicia Gray, and also under guidance of Dr. 




B.1. Structural information of Gal4 
Gal4 is an 881-residue protein, deletion analysis
20
 has shown that the N-terminal 147 
residues and the last 100 residues at the C-terminal are the key domains that govern DNA-
binding and transcriptional activation respectively.
21
 Further studies of Gal4 have used the 
simplified modular construct of these two domains with slight variations on sequence length.
21–26
 
Structural studies of Gal4 have mainly focused on the DNA binding domain (sometimes further 
categorized as a DNA binding domain and a dimerization domain)
27
, as this is a structurally 
stable domain. NMR and X-ray crystallography data have shown that the DBD binds to DNA via 




Figure 0.1 Structures of Gal4 domains. a) Various structures of the Gal4 DBD and the methods 
used to solve them. The structure of Gal4 (50-106) clearly shows different structural organization 
than that of Gal4 (1-100). This could be due to allosteric effects by residues 1-49 or by the DNA 
oligomer, or due to crystal packing that could occur in x-ray crystallography. b) Structure of a Gal4 
TAD peptide (red) bound to Gal80 (gray), its suppressor.  
 
Interestingly the conformation of the published DBD structures are quite different, likely 
caused by certain variables, such as domain length, structural method employed, and with or 
without DNA. The conformation of the transcriptional activation domain of Gal4, however, is 
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poorly understood, and the only structure of the TAD is a 21-residue peptide bound to its 
suppressor, Gal80 (Figure 0.1b).
30
 There is much more that needs to be understood about the 
conformational characteristics of the Gal4 TAD, as this is the domain of the protein that governs 
interaction with and recruitment of various different transcription factors.  
 
B.2 Using NMR to gain structural information of conformationally dynamic proteins  
The utilization of NMR techniques to obtain structural information of proteins has been 
steadily progressing over the past few decades.
10,31
 Today, NMR has been proven 
complementary to crystallography in producing protein structures.
32
 While crystallography 
can produce very specific atomic level structures, it relies heavily on a protein forming a 
homogenous crystal. Alternatively, solution NMR provides access to the solution structure 
and dynamics of protein. This method is even more desirable in studying the conformations 
of intrinsically disordered or conformationally dynamic proteins.
12,13
 It is harder for flexible 
proteins to crystallize, and even though various methods have been developed to aid their 
crystallization
33,34
 only one conformation will be captured, and might not comprehensively 
reflect the ensemble nature of these flexible proteins. NMR, on the other hand, does not 
require a homogenous solution, and can record an ensemble of conformations that could be 
flexible and “fuzzy” in certain regions.
35
 This gives us a more accurate view of the state of 
the protein in solution.  
Even more enticing, different NMR techniques can also provide insights into protein 
structure or dynamics without necessarily requiring complete structural data. In particular, 
valuable information is available through monitoring changes in protein chemical shifts 








C chemical shifts report on the 
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chemical and electric environment of a particular nuclei, which can be correlated to the 
local protein secondary structure.
36–40
 Common 2D NMR experiments for studying proteins 








C HSQC (heteronuclear single quantum correlation) 




C chemical shifts 
typically have greater dispersion than 
1
H chemical shifts, and it is possible to assign the 
chemical shifts of individual protein residues.
41
 This allows for higher resolution 
characterization of changes in protein structure or environment. The conformational 
information of many transcriptional activation domains have been probed by this technique. 
For example, 
15
N-labeled VP16 TAD was titrated with a binding partner PC4, and the 




N HSQC spectra identified two 
regions of VP16 TAD that were most effected by PC4 binding.
42
 Another example is the 




N HSQC spectra for 
the complex showed that 
1
H signals for the unstructured HIF-1α had greater dispersion beyond 
the random coil region (7.8-8.4 ppm) indicating that upon TAZ1 binding the unstructured HIF-
1α adopts an α -helical structure.
13,43





N HSQC spectra in different constructs could help us gain insight into the 
conformations adopted by different constructs of the protein.  
 
B.3. An NMR compatible solubility tag GB1 
  A common characteristic of many flexible proteins, especially transcriptional activators 
is the low solubility of the isolated protein in vitro. To this end, solubility enhancement tags 
are often fused to the N-terminal of the target protein. Unfortunately many of the common 
solubility tags, such as glutathione S-transferase (GST) and maltose binding protein (MBP), 
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are fairly large in size. This poses as a problem in NMR studies, as conventionally it is 
much harder to obtain high resolution spectra from larger proteins (>30 kDa).
44
 Cleaving the 
solubility tag after expression is not an option either, as most 2D NMR techniques require a 
sample concentration of approximately 100 μM. To address this problem, a much smaller 
solubility tag is often used in NMR studies, the 56 amino acid protein G B1 domain 
(GB1).
45
 This domain has been shown to be highly soluble, highly stable, and has minimal 
nonspecific interactions with target proteins.
46,47
 For these reasons, we have chosen to use 






N HSQC to study allosteric effects between Gal4 domains 
C.1. Gal4 TAD exhibits increased affinity to Med15 when fused to Gal4 DBD 
We noticed that the affinity of the Gal4 DBD-TAD fusion protein (Gal4 (1-100)-(840-
881)) to Med 15 (1-345) was much higher than that of the Gal4 TAD peptide (854-874) 
(Figure 0.2). While there were different solubility tags on Med15 (GB1 was used in the first 
experiment while GST used in the latter), the drastic difference of 20-fold cannot be simply 
explained by nonspecific interactions between solubility tags (GB1 does not dimerize  at the 
pH conditions used in this assay)
48
 or the small difference in the TAD sequences (residues 
855-870 were determined to play the most important role in TAD function)
49
. We then 
hypothesized that the fusion of the Gal4 DBD to Gal4 TAD allosterically affects the 
conformational dynamics of the TAD region. To test this hypothesis, NMR HSQC 




Figure 0.2 a) Schematic of components of the two separate assays. In the first assay, the C-terminus 
cysteine of Gal4 is labeled with a fluorescein, in the second assay, the N-terminus of Gal4 peptide is 
coupled with FITC. GB1 and GST are solubility tags fused to either Gal4 or Med15. b) Fluorescent 
polarization binding curves of Gal4 DBD-TAD (blue, right Y-axis) and Gal4 TAD (black, left Y-
axis) binding to Med15 (1-345). The Gal4 DBD-TAD binding assay shows smaller dynamic range 
due to the smaller difference in size after binding to Med15 compared to the Gal4 TAD peptide. 
Data for the Gal4 DBD-TAD assay were performed in triplicate; standard deviation is depicted as 
error bars. Data for the Gal4 TAD assay was performed in duplicate, standard deviation is depicted 
as error bars. KD values were obtained by fitting data in GraphPad Prism; standard error of fitting is 











N HSQC (heteronuclear single quantum correlation) NMR 
experiments were carried out first with a 
15
N GB1-Gal4 (840-881) construct. The resulting 
spectrum had clear resolution (Figure 0.3). GB1’s NMR assignments are already available
50
 
and have been assigned on the spectrum. The unassigned peaks are those of the Gal4 TAD, 
which are mostly in the random coil region between 7.8-8.4 ppm on the 
1





N HSQC experiments were carried out for 
15
N GB1-Gal4 (1-100) and 
15
N 
GB1-Gal4 (1-100)-(840-881). While these two constructs did not yield spectrum with 
optimal resolution, overlay of the three spectra (Figure 0.4) clearly show peak shifts in the 
GB1-Gal4 (1-100)-(840-881) spectra that correspond to the Gal4 (840-881) region display 
perturbation compared to that of isolated GB1-Gal4 (840-881). This suggests that there is 
indeed a certain degree of conformational change happening to Gal4 TAD when it is fused 
to the Gal4 DBD. (See Experimental methods section for details.) Also of note is that many 
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peaks have “disappeared” from the random coil region in the Gal4 (840 -881) spectra when 
Gal4 (1-100) is fused to it. While more vigorous controls and higher resolution data is 
required to be certain, this suggests some residues in the TAD might have assumed a more 






N HSQC spectrum of 
15
N GB1-Gal4 (840-881).  The annotated peaks are residues 









N HSQC spectra of 
15
N labeled GB1-Gal4 (840-881) (red), GB1-
Gal4 (1-100) (blue) and GB1-Gal4 (1-100)-(840-881) (green). The random coil region between 7.8-
8.4 ppm is indicated by vertical lines and zoomed in for better resolution. 
 
D. Future Directions 
There is still work to be done before definitive answers can be drawn on this study. First of 
all the residues in the Gal4 (840-881) HSQC spectra should be assigned. Many studies have been 
focused on predicting, identifying and calibrating chemical shifts in the random coil region,
12,51,52
 
which will be instrumental in this process. In addition, alternative detection methods such as 
13
C-
NMR can also be employed. Heteronuclear detection is advantageous for studying intrinsically 




N show much better random coil dispersion than protons.
53–56
 
Also, as mentioned in the Results section, poor resolution spectra were collected for the Gal4 
(1-100) and Gal4 (1-100)-(840-881) constructs. Identifying conditions to increase protein 
solubility are essential to recording high quality spectra. While the GB1 tag is necessary for 
protein solubility, it is possible that the increased molecular weight from the tag could decrease 
154 
 
spectral quality. One way to avoid this would be by introducing an NMR silent (non 
15
N labeled) 
tag: labeled GB1-Gal4 would be expressed and purified as usual, then an unlabeled GB1 tag can 
be ligated to the other terminus of Gal4 by a pre-installed protein ligation sequence, and the 
15
N 
GB1 tag is cleaved off at an introduced cleavage site.
46
 
Once the chemical shifts of Gal4 (840-881) are correctly assigned and the spectra of Gal4 (1-
100) and Gal4 (1-100)-(840-881) are obtained in high resolution, overlay of Gal4 (1-100) with 
Gal4 (1-100)-(840-881) will reveal the resonance peaks corresponding to the TAD region in the 
Gal4 (1-100)-(840-881) construct. These resonance peaks will then be compared to those of the 
assigned peaks in the Gal4 (840-881) spectrum to identify the residues that have shifted in 
conformation upon fusion to Gal4 DBD. 
 
E. Experimental Methods 
Protein Expression and Purification 
His6-GB1-tagged Gal4 proteins: The DNA sequences of Gal4 (1-100), Gal4 (1-100)-
(840-881) and Gal4 (840-881) were cloned into the plasmid pMCSG9 containing a His6-GB1 
tag at the N-terminus. Expression of proteins were carried out in Rosetta2 (DE3) pLysS E. 
coli cells (Novagen) as previously described.
57
 Briefly, cultures (50 mL) inoculated with 
single colonies were grown overnight at 37 °C (250 rpm) in Lennox L Broth (Research 
Products International) supplemented with ampicillin (100μg/mL) and chloramphenicol (34 
μg/mL) before dilution (50-fold) into 4x 1 L cultures of either Lennox L Broth (Research 
Products International) or minimal media M9 (including 
15
NH4Cl as previously described)
58
 
supplemented with ampicillin (100 μg/mL). After an OD600 of 0.4 was reached, protein over-
expression was induced with IPTG (final concentration 1 mM) in the presence of 20 μM 
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ZnSO4 for 5 hours. Cells in 50 mL culture were pelleted by centrifugation, resuspended in 10 mL 
lysis buffer A (10 mM Tris, pH 8.0 at 4 °C, 500 mM NaCl, 10% glycerol (v/v), 10 mM β-ME, 
0.1% Tween* 20 (v/v), and Roche Complete Protease Inhibitor Cocktail), then lysed using 
sonication. His-tagged protein was isolated by incubating cell lysate with 200 μL of Ni-NTA 
beads (Qiagen) for 1 hour at 4 °C, followed by washing with 8 times with 1 mL wash buffer A 
(20 mM Tris, pH 8.0 at 4 °C, 100 mM NaCl, 20% glycerol (v/v), 1 mM β-ME, 0.1% Tween* 20 
(v/v), 30 mM imidazole). The protein was eluted from the beads by incubation at 4 ºC overnight 
with 1 mL elution buffer A (20 mM Tris pH 8.0 at 4 °C, 100 mM NaCl, 20% glycerol (v/v), 250 
mM imidazole). The protein solution was buffer exchanged into storage buffer A (20 mM 
HEPES, pH 7.5 at 4 °C, 200 mM NaCl, 10% glycerol (v/v), 1 mM β-ME, 1 mM EDTA, 20 μM 
ZnSO4) using a PD-10 column (GE Healthcare), and the protein concentration was measured 
using absorbance at 280 nm.  The identity and purity (>90%) of the protein was verified by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  
GST-tagged Med15 (1-345): The DNA sequence of Med15 (1-345) was cloned into the 
plasmid pGEX containing a GST at the N terminus. Expression of GST-Med15 (1-345) was 
carried out in Rosetta2 (DE3) pLysS E. coli cells (Novagen). Briefly, cultures (50 mL) from 
single colonies were grown overnight at 37 °C (250 rpm) in Select APS Super Broth (Difco) 
supplemented with ampicillin (100μg/mL) and chloramphenicol (34 μg/mL) before dilution 
(100-fold) into 4 x 1 L of Select APS Super Broth supplemented with ampicillin (100 μg/mL). 
After an OD600 of 0.3 was reached, the cultures were cooled for 45 min at 16 °C (150 rpm), and 
expression was induced with IPTG (final concentration 0.1 mM) for 5-6 hours at 250 rpm. Each 
cell pellet was resuspended in 25 mL lysis buffer B (100 mM PBS pH 7.4 (Pierce), 0.2% NP-40 
Substitute (Fluka), 10% glycerol (v/v), 1 mM DTT and Roche Complete Protease Inhibitor 
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Cocktail), lysed using sonication, and the GST-tagged protein was isolated using Glutathione 
Sepharose 4B (GE Healthcare). The cell lysate was incubated with 2 x 1 mL of glutathione 
beads for 1 hour at 4 °C. The beads were washed 6 times with 10 mL wash buffer B (100 
mM PBS pH 7.4 (Pierce), 0.2% NP-40 Substitute (Fluka), 10% glycerol (v/v), 1 mM DTT), 
and the protein was eluted from the beads by incubation at 4 ºC overnight with 1 mL elution 
buffer B (50 mM Tris pH 8.0 at 4 °C, 0.015 M reduced glutathione, 0.1% NP-40 Substitute). 
Additional protein was eluted from the column by twice incubating the beads with elution 
buffer for 1 hour at 4 °C.  The protein samples were combined and concentrated using a 
Centriprep 10K centrifugal filter device before buffer exchange into storage buffer B (10 mM 
PBS pH 7.4 (Pierce), 10% glycerol (v/v), 0.01% NP-40 Substitute, 1 mM DTT) using a PD-
10 column (GE Healthcare).  The protein was then concentrated using a Vivaspin 30K 
centrifugal filter device, and the protein concentration was measured using absorbance at 280 
nm.  The identity and purity (>85%) of the protein was verified by reducing SDS-PAGE with 
appropriate molecular weight standards. 
GB1-tagged Med15 (1-345): The DNA sequence of Med15 (1-345) was cloned into the 
plasmid pMCSG9 containing a His6-GB1 tag at the N-terminus. The protein was expressed 
as described for GST-Med15 (1-345), and purified and verified for purity and concentration 
as described for the Gal4 proteins. 
 
Expression and Fluorescein Labeling of Gal4 Cysteine Mutant 
A cysteine residue was added to the C terminus of the His6-GB1-Gal4 (1-100)-(840-881) 
by site directed mutagenesis to create His6-GB1-Gal4 (1-100)-(840-881)-Cys. The protein 
was expressed and purified as described for His6-GB1-tagged Gal4 proteins. Fluorescein-5-
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Maleimide (Pierce) was dissolved in small amounts of DMSO, then added to His6-GB1-Gal4(1-
100)-(840-881)-Cys at 25-molar excess in labeling buffer (20 mM HEPES, pH 7.5 at 4 °C, 200 
mM NaCl, 10% glycerol (v/v), 1 mM TCEP, 1 mM EDTA, 20 μM ZnSO4). The reaction was 
incubated overnight at 4°C protected from light. Excess Fluorescein-5-maleimide was removed 
by desalting with a PD-10 column (GE Healthcare). The degree of labeling was calculated by the 
following equation: 
                                   
    
   [       ]   
                 
 
In this equation Amax is the absorbance of fluorophore (at 495 nm), and ε’ is the molar 




). The protein concentration is obtained 
by equation A.2, in which CF is the correction factor of A280/Amax=0.3 and ε is the molar 
extinction coefficient of the protein in question at A280. 
[       ]    
              
 
                 
 
The Gal4 protein was labeled with 50-60% efficiency, and concentration of the protein used 
in calculations for binding assays was corrected for the concentration of fluorescein-labeled 
protein. 
 
Peptide Synthesis and Purification 
The Gal4 TAD (854-874) peptide was synthesized and purified as previously described.
59
 
The sequence is as follows: 





Fluorescence Polarization Assays to Measure Gal4 affinity to Med15 (1-345) 
FITC-labeled Gal4 (854-874) peptide or Fluorescein labeled His6-GB1-Gal4(1-100)-(840-
881)-Cys were diluted in DNA-binding buffer (20 mM HEPES pH 7.5, 75 mM potassium 
acetate, 0.02 mM zinc sulfate, 4 mM magnesium acetate, 1 mM β-mercaptoethanol (βME), 0.05 
mM EDTA, 10% glycerol, and 0.1 mg/mL BSA) to a concentration of 100 nM. Then 200 µL of 
the DNA solution was added to a series of 50 µL solutions of varying Med15(1-345) 
concentrations in storage buffer B (10 mM PBS pH 7.4 (Pierce), 10% glycerol (v/v), 0.01% NP-
40 Substitute, 1 mM DTT) to obtain the final concentrations of up to 80 μM. The samples were 
incubated for 30 min at room temperature before the degree of fluorescence polarization was 
measured (Beacon 2000, Pan Vera Corp). A binding isotherm that accounts for ligand depletion 
60
 (assuming a 1:1 binding model of dimeric activator to duplex DNA) was fit to the observed 
mP values as a function of activator to obtain the apparent equilibrium dissociation constant, Kd: 
 
where “a” and “x” are the total concentrations of duplex DNA and dimeric activator, 
respectively, “y” is the observed polarization at any activator concentration, “b” is the maximum 
observed polarization value, and “c” is the minimum observed polarization value. Each data 
point is an average of either two or three independent experiments with the indicated error 





N-HSQC NMR Experiments 
Uniformly 
15
N labeled GB1-Gal4 protein was expressed and purified as previously described.  
A 50-150 μM solution of 
15








N HSQC experiments 
were recorded at 27 
o
C on an Avance Bruker 600 MHz NMR spectrometer equipped with a 
triple-resonance 5 mm cryogenic probe.  Data was processed using NMRpipe
61
 and analyzed in 
Sparky (UCSF).
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